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ABSTRACT

EXPRESSION AND IN VITRO PHOSPHORYLATION OF THE YEAST
TRANSCRIPTIONAL ACTIVATOR ADR1
BY
Joel R. Cherry
University of New Hampshire, Septem ber, 1988

The ADR1 protein activates transcription of the gene coding for the glucose
repressible alcohol dehydrogenase II (ADH2) in Saccharomyces cerevisiae.
Previous characterization of ADRjC mutations, which allow ADH2 to escape
glucose repression, led to the hypothesis that ADR1 is inactivated posttranslationally by a cAMP-dependent phosphorylation mechanism. This
hypothesis w as tested by investigating the in vitro phosphorylation of ADR1
and ADR1C proteins in which ADR1C proteins were predicted to display a
diminished level of phosphorylation. A fragment of the ADR1 g en e coding for
the N-terminal 658 amino acids was fused to the lacZ gen e of E. coli to allow
for identification and a ssay of the ADR1 protein. The fused gene w as placed
under the control of the E. coli

lac promoter to

ensure efficient production.

B eta-galactosidase activities in plasmid-bearing E. coli indicated that ADR1/6galactosidase fusion proteins were being expressed. SDS-polyacrylamide gel
analysis of E. coli extracts revealed discrete plasmid-encoded fusion proteins.
Fusion proteins contained in crude E. coli extracts w ere phosphorylated in

vitro using purified catalytic subunit of mammalian cAMP-dependent protein

kinase (cAPK). Peptide mapping results indicated that ADR1 w as
phosphorylated at two discrete sites in vitro. The primary phosphorylation site
w as identified a s serine-230. A secondary site to the N-terminal side of serine230 w as also identified.
ADR1 DNA seq u en ces were replaced in the expression plasmids with three
seq u en ces containing ADR1C mutations, each of which encodes a single
amino acid substitution within the phosphorylation sequence located between
residues 227-231 (Arg-Arg-Ala-Ser-Phe). The in vitro phosphorylation of
ADR1 and ADR1C containing fusion proteins were com pared using both bovine
cAPK and the yeast cAPK catalytic subunit encoded by the TPK1 gene.
Addition of purified yeast regulatory subunit completely blocked fusion protein
phosphorylation by the y east kinase in the absence of cAMP. The ADR1-2C and
ADR1-50 mutations were found to diminish phosphorylation at serine-230. The
ADR1-7C mutation, which substitutes a leucine residue for serine-230,
completely eliminated phosphorylation.
The results of this work support the hypothesis that the ADR1C proteins
bypass glucose repression by avoiding phosphorylation and suggest that ADR1
is regulated by a cAMP-dependent phosphorylation. Possible m echanism s by
which phosphorylation may regulate ADR1 activity are discussed.

xii

I. INTRODUCTION
The ability of an organism to respond physiologically to changes in its
environment is often dependent on the precise and timely control of gene
expression. In the yeast Saccharomyces cerevisiae proteins of the respiratory
chain, glyoxylate cycle and gluconeogenesis are repressed when the organism
is grown in medium containing a fermentable carbon source such a s glucose1'
11. When the fermentable carbon source is depleted, however, synthesis of
proteins such a s iso-1 -cytochrome c2, citrate synthase10, and alcohol
dehydrogenase II11 is derepressed. Thus by altering its pattern of gene
expression, yeast is able to metabolically adjust to chan g es in the availability of
glucose. While the expression of many proteins is known to be modulated in
response to chan g es in the extracellular environment, little is known about the
molecular m echanism s responsible for th e se changes. B ecause yeast are
easily m anipulated using both the techniques of classical genetics and
molecular biology, it represents an ideal organism in which to study the control
of eukaryotic gene expression. The present work investigates the mechanism
by which the positive regulator ADR1 controls alcohol dehydrogenase II
expression in yeast.
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Alcohol dehydrogenase II (ADH II) is one of three active ADH isozymes
found in S. cerevisiae. The metabolic function of two of the isozymes, ADH I
and ADH II, w as elucidated by the studies of Lutsdorf and Meg net11. The
classical fermentative isozyme, ADH I, is a cytoplasmic enzym e which catalyzes
the NADH-linked reduction of acetaldehyde to ethanol13. ADH I plays a vital
role in the ceil during anaerobic growth by regenerating NAD-*- for use by the
glycolytic enzym e glyceraldehyde-3-phosphate dehydrogenase. The ADH II
isozyme is also localized to the cytoplasm, but appears to kinetically favor
catalysis of the opposite reaction - the NAD+ linked oxidation of ethanol to
acetaldehyde14. ADH II allows y east to utilize ethanol a s an energy and carbon
source when glucose is unavailable. Cells unable to produce the fermentative
isozyme du e to mutation of the ADH1 gene* are viable under glucose growth
conditions, but grow slowly due to the need to metabolize glucose aerobically.
The other isozyme, ADH III, is expressed at very low levels14. Cells lacking this
mitochondrially-associated isozyme are viable and appear not to be defective in
any cellular functions, indicating that ADH III performs no essential metabolic
function.
Transcription of the the classical fermentative isozyme, ADH I, is activated
"Throughout this work three letter gene designations will be underlined a s is
customary in yeast genetics. Three letter designations not underlined refer to
the protein products i.e., ADB1 gene, ADR1 protein.
2

during growth in the presence of glucose and d e crea se s approximately six-fold
when cells are transferred to medium containing a nonfermentable carbon
source such a s ethanol15. ADH II expression, on the other hand, is repressed at
the level of transcription when cells are grown in the presence of glucose16.
Magasanik, who dem onstrated in bacteria that the repression of enzyme
synthesis in response to glucose is mediated by som e glucose catabolite rather
than glucose itself, term ed this catabolite repression17. ADH2 h as com e to be
referred to a s a catabolite repressed gene, and the term may be apt since
ferm entable sugars other than glucose have been dem onstrated to repress
ADH II expression12.
When glucose is depleted from the growth medium or cells are grown in
medium containing nonfermentable carbon sources, ADH II enzym e activity
increases approximately 500-fold a s ADH2 mRNA production is derepressed16.
Derepression of ADH2 w as first determined by Ciracy18*20 to be dependent
upon the presence of the two trans-acting regulatory g e n es ADR1 and CCR1.
Denis21 later dem onstrated that there are two regulatory pathways controlling
ADH2 expression: one consisting of the previously characterized positive
activators ADR1 and CCR1. and the other consisting of a positive effector,
CCR4. w hose activity is controlled by two negative effectors CRE1 and CRE2 a s
illustrated below:

3

ADH2

t

ADR1

t+

CCR1

CCR4

/

V

CRE1

C R E2

This model w as based on the epistatic relations of the various regulatory loci
and does not necessarily imply that the proteins they encode interact directly.
B ecause ADR1C mutations could be isolated which activated ADH2 expression
in the ab sence of a functional CCR1 gene, Denis concluded that ADR1 more
directly affects ADH2 than d o es CCR1. ADR1 appears to be specific for the
regulation of ADH2 expression since it d o es not affect the activities of several
other enzym es subject to catabolite repression21,22. A recent report by Bemis
and Dents23 concludes that ADR1 is required for growth in medium containing
glycerol a s the sole carbon source, although did not found affect the activity of
som e enzym es involved in glycerol metabolism. ADR1 may therefore control a
process required for the growth of cells in medium containing nonfermentable
carbon sources other than glucose, but d o e s not ap p ear to be a general
activator of catabolite-repressed genes. In contrast, CCR1 and CCR4 are
pleiotropic activators which have been shown to affect the expression of several
glucose-repressed enzym es19,21. They may therefore encode proteins which
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play a more universal role in transcription than does ADR1.
The ADR1 g e n e has been cloned24 and sequenced25 and is predicted to
en co d e a protein 1323 residues in length with a calculated molecular weight of
151 kilodaltons (KDa). ADR1 h a s been shown to be localized to the yeast
nucleus via a targeting sequence within its N-terminal 642 amino acids26,
indicating that the protein may be intimately involved with the transcription of
APH2.
ADR1 function has been elucidated largely through the characterization of
recessive adr1 mutations and dominant ADR1C mutations. Strains carrying
recessive adr1 mutations are unable to derepress transcription of ADH2
normally, while strains carrying an ADR1° allele allow ADH2 transcription to
occur in medium containing glucose.
The first of the ad rl mutations to be characterized, ad rl-1 . w as found to
contain an um ber mutation at th e eleventh codon position which blocks
translation of the ADR1 protein (Lynne Bemis, personal communication).
Strains carrying this allele have virtually no ADH II enzyme activity18, indicating
th at th e ADR1 protein is essential to derepress transcription of ADH2 fTable 1a).
Strains carrying other a d d -ty p e mutations fail to derepress ADH2
transcription to varying extents (Figure 1a). T hese mutations were found to
en co d e ADR1 proteins containing single amino acid substitutions within a
region which sh a re s homology with the "zinc finger" DNA-binding seq u en ce

Table 1.
a . ADH II Enzym e A ctivities
Relevant
G enotype
adr1-1
ADR1

ADH II Specific Activity (mU/mq)
G lucose
Ethanol
2
5

10
2500

ADR1-2C.4C
ADR1-5C

200
370

3500
3400

ADR1.:7.C

250

2800

ADH II activities were taken from Cherry et al.27 with the exception of the
values for the adr1-1 allele, which were taken from Bemis and Denis23. ADH II
activities were determ ined a s described16 following growth of cultures overnight
at 30° C. Culture mediums contained YEP medium (2% yeast extract, 1%
Bacto-peptone, 20 mg/L adenine and uracil) supplem ented with either 8%
glucose or 3% ethanol.

b. Identity of the C onstitutive ADR1 M utations

ADR1 allele

b a se pair
ch an g e

nucleotide
num ber

amino acid
ch an g e

residue

A D R 1 -2 °4 C
ADR1-5C

T to C
G to A

692
683

Phe to S er
Arg to Lys

231
228

ADR1-7®

C to T

689

S er to Leu

230

The identity of the ADR1-5C mutation is presented a s reported by Denis and
Gallo32. The identities of the ADR1-2C. ADR 1-4°. and ADR1-70 mutations are
presented a s reported by Cherry et al.27
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Figure 1
a.

ADH II A ctivities of Strains Bearing a d r1 -5 c -x M utations
ADH II Soecific Activity fmll/mol
Glucose
Ethanol

Relevant
Genotype

adri-5c:5

16

1100

adr1-5°-2

1

11

a d n -5 c-a

0

APF^1-5C

370

137
3400

ADH II activities were taken from Ref. 97 with permission from the author.
ADH II activities w ere determined a s described16 following growth of cultures
overnight at 3 0 ° C. Culture mediums contained YEP medium (2% yeast extract,
1% Bacto-peptone, 20 mg/L adenine and uracil) supplem ented with either 8%
glucose or 3% ethanol.
b.

Location of adr1-x Amino Acid Su bstitu tion s in th e Putative Zinc
L j y —Cly—S tr-F r*

F in ger
S«r

Vb«
\

Clu—V*l
*'S. /

\ Zn“/

'

_
/
A la
-v

/\

H I.
Tkr

L ,. ^
(ad lk Z l

T»r

/

VA**/■

Au

i,

cfu^_

I
»

Gly

^m

Ln

'•T*
s™

\ Zn"
/

<«d»l.4>Tjrr _

/ \I

''•n .- n r

TA

*
Jlf

lyi—Cl»

Taken with permission from ref. 98. Drawn by D. Mullaney a s adapted from
Hartshorne et al. (ref. 25).
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motif first noted in the 5S rRNA transcriptional activator TFIIIA of Xenopus
/aev/s26,27. T hese fingers, which a re repeated nine times in TFIIIA28, are
repeated twice in AOR1 and occur between residues 98-126 and 127-155.
Hartshome et al.25 have proposed, by analogy to TFIIIA, that th e se regions of
ADR1 form functional DNA-binding structures by coordinately binding Zn2+ ions
a s illustrated in Figure 1b.
This proposal is consistent with numerous stu d ies which suggest that the
ADR1 protein activates transcription of the ADH2 g en e by binding directly to a
region of DNA centered approximately 230 b a se pairs (bp) upstream of the
ADH2 transcription start site. This region, term ed a n upstream activating
sequence or UAS, contains a 22 bp perfect inverted repeat. Deletion of the
UAS from the ADH2 upstream region eliminates ADR1 -m ediated
transcription

pg oq

' . Conversely, transcription of ADH2 was inhibited by

placem ent of upstream sequences on multi-copy plasmids31. Inhibition w as
relieved by placing a copy of the ADR1 gene on th e sam e plasm id31,
presumably a s a result of increased ADR1 expression. T hese results suggest
that ADR1 interacts directly with th e ADH2 UAS a n d that this interaction is
essential to transcription.
The ADR1 protein may well require the zinc finger structures for binding to
the ADH2 UAS. While metal binding has not yet b een dem onstrated for the
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intact ADR1 protein, a synthetic peptide comprising amino acids of the Cterminal finger have been dem onstrated to bind Zn2+ ions. Metal-dependent
DNA binding w as observed, but the peptide:Zn2+ complex failed to bind
specifically to ADH2 upstream se q u en c es (G. Parraga, personal
communication). Therefore it appears that the fingers are necessary but not
sufficient for sequence-specific binding of ADR1 to DNA. They may simply
stabilize general ADR1-DNA interactions while the seq u en ce specificity of
DNA-binding is conferred by other seq u en ces on the ADR1 protein.
S equences just N-terminal to the fingers have been implicated in such a role (T.
Young, personal communication), but the mechanism of interaction h as yet to
be elucidated. Regardless of the role the finger regions play in ADR1 function, it
is evident from the ADH II activities in strains carrying this second class of adr1
mutations that th ese regions are essential to ADR1 activity.
Like the second class of adrl mutations, the ADR1C mutations w ere found to
encode single amino acid substitutions within the ADR1 protein (Table 1b), but
with a different effect on ADH2 expression27'32 (Table 1a). T hese mutations
allow ADH2 expression to partially overcom e glucose repression, in som e
c a se s increasing ADH II activity by 70-fold (Table 1a). Furthermore, since ADR1
mRNA h as been shown to be constitutively expressed and is independent of the
ADR1 allele32, this d ata implies that the ADR1 protein is present but inactive

under glucose repressed conditions. The ADR1C m utations must encode
mutant proteins which can partially bypass the ADR1-inactivation mechanism.
Such a system of post-translational control of ADR1 is supported by studies
which exam ined the effect of increased ADR1 gene dosage on ADH2
expression33. Previous studies had shown that ADH II activity is directly related
to the level of ADH2 mRNA transcribed16, therefore ADH II activities were used
to provide a m easure of ADR1 activity. ADH II activities in glucose-grown cells
w ere observed to increase linearly a s the ADR1 gene dosage w as increased. A
similar effect w as observed in strains with increased ADR1-50 d o sag es,
indicating that the linear increase in ADH2 expression w as the result of
increased levels of ADR1 protein. In contrast, under derepressed growth
conditions ADH It activities increased with increased ADR1 dosage until a
maximum ADH II activity w as approached asymptotically. Strains carrying two
to three copies of ADR1 had ADH II activities approximately one-half that of
strains carrying a s many a s 75 copies of ADR1. ADH2 expression in strains
with high ADR1 dosage w a s observed to increase w hen the d o sag e of ADH2
w as increased, indicating that during derepression ADH2 expression w as
limited by the d osage of the ADH2 gene. These results imply that during
glucose repression transcription of ADH2 is limited by the level of ADR1 protein,
but that under d erepressed conditions ADR1 protein can nearly activate ADH2
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transcription maximally. Increased levels of ADR1 protein may therefore
override som e mechanism which normally inactivates ADR1 during glucose
repression. Because strains with increased ADR1 d o sag e are phenotypically
similar to strains with an ADR1C allele, the sam e ADR1 protein inactivation
mechanism may be overridden or bypassed in both c a se s.
Characterization of th e ADR1-50 mutation prompted Denis and Gallo32 to
propose that the post-translational modification which renders ADR1 inactive
during glucose growth is a cAMP-dependent phosphorylation of the ADR1
protein. The sequence Arg-Arg-Ala-Ser-Phe lying betw een residues 227-231
of ADR1 is homologous to sequences recognized by type II cyclic AMPdependent protein kinases (cAPK), Arg-Arg-X-Ser-Y, w here Y tends to be a
hydrophobic residue, X is not conserved, and the serine serves a s the
phosphoacceptor34,35. Four of the ADR1C constitutive mutations w ere cloned
and sequenced, and all four were found to alter residues within this cAPK
phosphorylation consensus site (Table 1b). ADR1-5C. th e first of the constitutive
mutations to be characterized, was found to encode a protein in which the
arginine residue at position 228 w as replaced by a lysine32. A synthetic peptide
containing an ADR1-5c-like alteration in the phosphorylation co n sen su s
seq u en ce w as determ ined by Kemp et al.35 to increase the Km of
phosphorylation 16 fold relative to an ADR1-like sequence (see Figure 2).
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Similarly, the ADR 1-2° and ADR1-4C mutations, which w ere found to be
identical (hence only ADR1-20 will be discussed), cause phenylalanine 231 to
be replaced by a serine27. Alteration of this amino acid, which is adjacent to the
phosphoacceptor serine and normally occurs a s a hydrophobic residue, might
also be expected to diminish phosphorylation by analogy to peptide studies
carried out by Bramson et al.36 (Figure 2). The fourth constitutive mutation
characterized, ADR1-7C. alters the putative phosphoacceptor serine to a
leucine27. Such a change would of course be expected to completely block
phosphorylation at this site. Therefore all four of the constitutive mutants of
ADR1 isolated thus far would be expected to diminish or eliminate
phosphorylation of ADR1 at serine 230. B ecause the ADR1C proteins are able
to c a u se a significant escape from glucose repression but only moderately
elevate the level of ADH II expression in the ab sen ce of glucose, reversible
phosphorylation of ADR1 w as suggested by Denis and Gallo32 to be involved in
the glucose repression of ADH2.
cAMP may therefore be one of the cellular signals which m ediates glucose
repression of ADH2. cAMP h a s been suggested to be involved in the
inactivation of num erous enzym es necessary to nonfermentative growth in
y e ast including m alate dehydrogenase37-39, fructose-1,6-bisphosphatase38*41,
and phosphoenolpyruvate carboxykinase39. In the c a se of fructose-1,6bisphosphatase Tortora et al.45
12

Figure 2.
The Effect of Amino Acid Su bstitu tion s on the K inetics of S yn thetic
P eptide P hosphorylation by B ovin e cAPK

Kemp synthetic peptide ("Kemptide");
Leu

Arg

Arg

A la

L ys
Km increases
16 fold
(Kemp et al.)35

Ser

L eu

G ly
v/Km d
ecrea se s
Vmax/Km
decreas
100 fold
(Bramson et al.)

Qfi

ADR1 protein sequence (residues 226-232):
(226) Thr

Arg

Arg

A la

Lys
(ADR 1-5°)

Ser

Phe

Leu
(ADR1-7C)

13

Ser

(232)

S er

WB^2PrAc)

dem onstrated that cAMP-dependent phosphorylation of the y east enzym e
reduces its catalytic activity and is a necessary step in its proteolytic
degradation. cAMP-dependent phosphorylation is also known to be involved in
th e regulation of trehalose and glycogen metabolism in yeast. The enzym es
responsible for the synthesis and breakdown of the disaccharide trehalose,
trehalose synthase and trehalase, are controlled coordinated by cAMPdependent phosphorylation. Phosphorylation increases the enzymatic activity
of trehalase43, while phosphorylation d ecreases the activity of the trehalose
synthase complex42. A similar coordinate control system h as also been
determ ined to regulate enzym es involved in glycogen metabolism44. In all of
th e se c a se s the cAMP signal alters enzym e activity through direct
phosphorylation of the protein. Interestingly, fructose-1,6-bisphosphatase
contains significantly m ore phosphorylated serine residues when isolated from
cells grown in medium containing glucose than in cells grown in medium
containing a nonfermentable carbon source41. This implies that cAMPdependent phosphorylation is stimulated by the presence of glucose. Glucose
h a s been observed to c a u se a dramatic, transient increase in the intracellular
cAMP concentration in y east46"48. In sum, the evidence sug g ests that in yeast
glucose c a u s e s increased cAMP-dependent phosphorylation of many proteins
necessary for nonfermentative growth.
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The enzym es presumably responsible for th ese phosphorylations, the yeast
cAM P-dependent protein kinases (cAPK) are encoded by four genes, three of
which encode catalytic subunits (TPK1. TPK2. and TPK3)49 while one codes for
a regulatory subunit (BCY1)50. The yeast cAPK, like its mammalian
counterparts, exists a s an inactive complex of regulatory (R) and a catalytic (C)
subunits in the absence of cAMP. When cAMP levels are increased the R
subunits bind cAMP, causing dissociation of the complex and freeing active C
subunits. In vitro studies indicate the yeast cAPK responds to cAMP in a
m anner analogous to the mammalian cAPK51, but the subunit stoichiometry in
the active and inactive com plexes has yet to be determined.
Of the three yeast catalytic subunits isolated thus far, only C 1 (encoded by
TPK11 has been characterized biochemically52. In studies using synthetic
peptides m odeled after the mammalian cAPK consensus sequence
("Kemptide"), C1 w as shown to be capable of phosphoiylating this ADR1-like
seq u en ce with a Km approximately 20-fold higher than the mammalian cAPK52.
Y east strains deficient in any two of the three TPK g e n es are viable, while
strains lacking all three TPK g e n es grow very slowly49. This indicates that the C
subunits which th ese g e n es encode recognize sufficiently similar seq u en ces
that they can functionally substitute for one another in the cell. One of the C
subunits may therefore be responsible for a glucose-dependent
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phosphorylation of ADR1.
The objectives of this work were to answer th e following questions
concerning the phosphorylation of ADR1:1) Is ADR1 phosphorylated by cAMPdependent protein kinase in vitro? 2 ) if so, at what site(s) is it phosphorylated?
and 3) do the characterized ADR1 constitutive m utations <ADR1-2C.ADR1-5C.
and ADR1-7C) eliminate or diminish phosphorylation of ADR1 by cAPK?
To study the phosphorylation of the ADR1 protein it was necessary to create
a fusion protein which would allow both qualitative and quantitative detection of
ADR1. To this end various fragm ents of ADR1 or ADR1C were fused to the lacZ
gene of E. co/rand placed under the control of suitable yeast or E. coli
promoters. G ene fusions on appropriate plasmid vectors were u sed to express
ADR1/B-Galactosidase fusion protein in either organism , depending on the
promoter contained in the plasmid constructs. T he presence of such fusion
proteins w ere then detected by published assay techniques in both cells
extracts and whole cells, be they y east or E coli. In yeast, plasm ids were
expected to express fusion protein with two determinable functions- 6galactosidase and ADR1. ADR1 activity would b e m easured indirectly by
assaying ADH II activity in strains in which the only functional ADR1 would be
encoded by the plasmids.
Fusion proteins detectable in crude extracts w ere phosphorylated in vitro
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using purified bovine or yeast cAPK in conjunction with radiolabeled ATP.
Phosphorylated fusion proteins were exam ined by immunoprecipitation with
anti-ADR1 or anti-0-galactosidase antibodies followed by fractionation on SDSpotyacrylamide gels. Determination of the site(s) of phosphorylation in ADR1
w as determined by peptide mapping of chymotryptic peptides derived from the
phosphorylated fusion proteins.
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II.

MATERIALS AND METHODS

E. coli an d Y ea stS tra in s. £ coli strains M182 (F', A(lac IOPZYAJX74, gal

U, gal K, strAr) and RR1 (F‘, hsds20 (rg‘ , m g’), supE44, ara-14, proA2 , lacY1,
galK2, rpsl_20 (strO, xyl-5, mtM.X*) w ere used. Y east strain 500-16 (M ATa
ad h 1-11 adh3adr1-1 trp1 ural his41 contains a nonsense mutation in ADR1 (L.
Bemis, personal communication).
Growth Conditions. £. coli were grown overnight at 37° C in L broth (1%
tryptone, 0.5% yeast extract, 0.5% NaCI, pH 7.5) containing ampicillin at a
concentration of 50 pg/ml. Twenty milliliter cultures w ere used for protein
analysis and 1.5 ml cultures were routinely used for plasmid DNA isolations. 3galactosidase expression w as screened for using MacConkey-lactose indicator
plates containing ampicillin (50 g/L BBL MacConkey Agar (BBL Microbiology
System s, Cockysville, MD), 25 mg/L ampilcillin). Colonies which appeared
bright red after overnight growth indicated the presence of cells expressing
levels of B-galactosidase activity in e x c e ss of 500 U/mg soluble protein.
Y east w ere grown in 2 ml cultures overnight at 30° C with constant shaking .
YEP medium (2% bactopeptone, 1% y east extract, 20 mg/L adenine and uracil)
containing 8% (w/v) glucose (YEP-GIc) or 3% ethanol (YEP-Et) w as used for
non-selective growth. W here indicated, the respiratory inhibitor antimycin A
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w as added to a concentration of 0.6pg/L. Trp~ medium contained 6.7 g/l yeast
nitrogen b ase, 20 mg/mi adenine, uracil, and tyrosine, 5 g/L casamino acids,
and 10 ml/L Trp dropout solution (0.5 g valine, 0.5 g threonine, 0.6 g
phenylalanine, 0.2 g methionine, 0.4 g lysine, 0.6 g leucine, 0.6 g isoleucine,
0.2 g histidine, and 0.2 g arginine in 100 ml water) and w as supplem ented with
either 8% glucose (Trp-GIc) or 3% ethanol (Trp-EtOH). Selective plates u sed to
screen for (3-galactosidase expression consisted of Trp-GIc medium buffered to
pH 7 with 0.1 M potassium phosphate (5.32 g/L KH2PO4 ,1 0 .6 3 g /L K2 HPO4)
and supplem ented with 25 g/L bactoagar. Ju st prior to u se , 100 pi of X-Gal (5bromo-4-ch!oro-3-indoyl-6-D-ga!actoside, 2% in dimethyl formamide) w a s
spread on the plate surface. Cells expressing 8-galactosidase activity in excess
of 0.5 U/mg soluble protein appeared dark blue after two d a y s growth at 30° C.
Plasmids. Plasm ids used in this work are listed in T able 2. The 5' ADR1
DNA se q u en c es used in the construction of plasmids JC 200Z and JC 25 w ere
derived from plasmid J S 1 19 constructed by Jeff Schuster a t Chiron Inc.,
Emeryville, CA. Plasmid JS 1 19 contains an Nco I site at th e start ATG of ADR1
resulting from the ligation of a synthetic 56 bp oligonucleotide to the 5' Hinc II
site at bp +48 of ADR1. This oligonucleotide conservatively replaces th e 5* end
of ADR1 while providing a new Nco I site at bp -1, and a new Bgl II site a t bp -7
(Table 2b).
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Table 2a.

P lasm id s U sed in C on struction s

Plasmid

Fragment of interest

S ource

pBR322

(E coli vector)

BRL

pUC19

(E coli vector)

BRL

YRp7-ADR1 -23A-6-5

ADR1

C. Denis27

YRp7-ADR1 (ABcl)

ADR1

A. Rovelli*

ADR1 and G3PDH promoter

JS 1 1 9

J. Shuster*

YRp7-ADR1 -5C-23A

ADR1-50

C. Denis24

YRp7-ADR1-2c

ADR1-20

C. Denis27

YRp7-ADR1-7c

ADR1-7C

C. Denis27

PKK240-11

tag promoter

M. Ptashne55

pRB45

lacZYA

M. Rose54

pSK S105

lacZYA

M. C asadaban

*These plasmids are described in Materials and Methods.
Table 2b.

O ligon u cleotid e S e q u en ce U sed In th e C onstruction of
JS119

Met Ala Asn Val Glu Lys Pro Asn Asp Cys Ser Gly Phe Pro Val
AGA TCT ATT ACC ATG GCT AAC GTT GAA AAG CCA AAC GAT TGT TCT GGT TTT CCA GTT
TCT AGA TAA TGG TAC CGA TTG CAA CTT TTC GGT TTG CTA ACA AGA CCA AAA GGT CAA

Bgl llA

Nco lA

Hinc llA
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Plasmid YRp7-ADRl-3l 1ABcl used in the construction of plasmid JC 1Z w as
constructed by Ann Rovelli in the Denis Laboratory by digestion of plasmid
YRp7-ADR1-31124 with Bel I and subsequent religation. The resulting plasmid
is identical to plasmid YRp7-ADR1-311 except that it lacks ADR1 sequences
from bp -1600 to bp +440.
Plasmid Constructions.

Restriction enzym es, bacterial alkaline

phosphatase, and DNA ligase were purchased from New England Biolabs
(Beverly, MA) or B ethesda R esearch Laboratories (Bethesda, MD). Plasmid
purification from bacterial cells w as performed essentially according to the
method of Birnboim and Doly53 and is described in Appendix A. Restriction
digestions w ere performed according to the m anufacturers' specification using
the LS, MS, HS or KS buffers described in Appendix B. DNA fragm ents w ere
separated by agarose gel electrophoresis in TAE buffer and visualized under
UV light after staining with ethidium bromide a s described by Maniatis et al.57
DNA ligations were performed a s described in Appendix C. E. coli
transformations were performed using com petent RR1 or M182 cells either
purchased from BRL (Bethesda, MD) or cells prepared by th e CaCl2 procedure
described by Maniatis et al.57 When necessary, transform ants were screened
by colony hybridization using an appropriate 32P-labeled ADR1 probe a s h as
been described58.
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Preparation of Soluble Protein Extracts from Y east

Cells were recovered

by centrifugation of overnight yeast cultures and cell pellets were washed once
using 2 ml buffer A:200 ( 25 mM HEPES, pH 7 .5 ,5 mM MgCfc, 1 mM EDTA, 5
mM B-mercaptoethanol, 1 mM phenylmethylsulfonyl chloride, 2 pM pepstatin,
0.6 pM leupeptin, 200 mM KCI). W ashed cells were resuspended in 200 pi
buffer A:200 and glass b ead s (0.5 mm in diameter) were then added at a ratio of
approximately 1g per 100 pi cell suspension. Cells were then lysed at 4° C by
vigorous mixing for approximately five minutes. Extracts were separated from
the glass beads, spun in a microcentrifuge for five minutes to rem ove insoluble
debris, and stored on ice for immediate assay.
Preparation of Soluble Protein Extracts from E. coli.

20 ml cultures were

se ed e d with a single red colony off of a Mac-AMP plate and grown overnight at
37° C. The cells were collected by centrifugation at 3000 X g, transferred to 1.5
ml microcentrifuge tubes, and washed twice with 500 pi buffer A:200. The
w ashed cells were resuspended in 500 pi of buffer A:200 and lysed by
sonication at 0° C. Sonication w as performed for 15-20 seconds at 80% power
using the 4 mm probe of a Biosoniks Sonicator (VWR scientific, Brunswick, NJ).
Extracts appearing translucent after sonication indicated efficient lysis a s
judged by protein determination and B-galactosidase activity m easurem ents
(data not shown). Sonication of extracts for time periods in e x c e ss of 30
seco n d s resulted in loss of m easurable enzym e activity. Extracts appearing
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o p aq u e after after initial sonication were cooled on ice and sonicated for 5 to 10
additional seconds. Translucent extracts w ere centrifuged at full sp e ed (13,000
X g) in a microcentrifuge for 15 minutes before removal of the supernatant
fraction containing soluble proteins. Extracts were then placed on ice for
immediate a ssa y or frozen in a dry-ice/ethanol bath for long-term storage.
Extracts could be stored for up to one month at -70° C with no appreciable loss
in B-galactosidase enzyme activity.
Native Polyacrylamide Gel Electrophoresis. Native polyacrylamide gels
59

w ere run a s described .
Sodium Dodecvlsulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE1.
Electrophoresis w as performed according to the method of Laemmli
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with

minor changes. Sam ples w ere mixed 1:4 with 5X SDS sam ple buffer (m ade by
mixing a warm solution containing 5 ml glycerol, 1 g SDS, and 2.5 ml 0.125 M
Tris, pH 6.8 with 14.6 M B-mercaptoethanol in a 3:1 ratio just prior to use) and
placed in a boiling w ater bath for 3 minutes just before application to the
polyacrylamide gel. Bromophenol blue w as added to the upper buffer cham ber
a s a tracker dye.
G els were stained for protein using Kodak Kodavue (Rochester, NY), the
G elcode silver stain of Pierce Chemical Co., Rockford, IL., or using the silver
stain protocol of Wray et al.61
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in Situ Staining of Protein Extracts with B-Galactosidase Activity. Native

polyacrylamide gels w ere stained for B-galactosidase activity by washing for 15
go
minutes at 37^ C with Z buffer (0.1 M sodium phosphate p H 7 .0 ,10 mM KCI,
^

imM MgS0 4 ) supplemented with 10 mM MnCl2 . Gels w ere then placed on a
glass plate with a white background and coated with 200 pi Bluogal (BRL, 2%
solution in dimethylformamide). After incubation at room tem perature for 15-20
minutes, proteins having B-galactosidase activity appeared a s blue bands.
Extracts containing a s low a s 50 to 100 units of B-galactosidase activity
routinely yielded visible, albeit diffuse, bands.
B-galactosidase and ADR1 /B-galactosidase fusion proteins present in
extracts fractionated on SDS-PAGE were detected by activity staining .
Electrophoresis w as performed a s described
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except that sam ples w ere not

boiled after addition of sample buffer. After electrophoresis gels were first
w ashed with water a n d then w ashed twice for 30 minutes in 250 ml 10 mM Tris,
pH 9, with water rinses between w ashes. After an overnight wash in Tris, gels
were rinsed in w ater and washed for an additional 2 hours in Z buffer
supplem ented with 10 mM MnCl2 to activate th e enzyme. Gels were then
placed on a white-backed glass plate and stained a s w as described above for
native gels. Gels w ere covered with plastic wrap to prevent them from drying
out and were allowed to develop for approximately two hours. Extracts with less
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than 300 units of B-galactosidase activity did not yield visible bands.
ADH A ssays. A ssays of ADH activity in y east extracts w ere performed as
previously described16 by mixing 0.89 ml ADH a ssay buffer (18 mM sodium
pyrophosphate pH 8.8 , 2.5 mM NAD+), 10 pi extract, and 100 pi 3 M ethanol in
a 1 ml cuvette and measuring the change in absorbance at 340 nm. An
extinction coefficient of 6.22 mM'1cm *1 was used for NADH. Activities are
reported a s millillnits ADH activity per mg protein where one Unit of ADH
activity is defined a s pm oles NAD+ reduced min"1 at 22° C. Protein a ssa y s
were performed by the method of Lowry
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using bovine serum albumin a s the

standard.
B-Galactosidase Enzvme Assays. E. coli and yeast extracts were assayed
62
essentially a s described by Miller . Assay reaction mixes generally contained
0.99 ml Z buffer, 10 pi soluble protein extract, a n d 0.2 ml o-nitrophenyl-B-Dgalactoside (4 mg/ml in 0.1 M phosphate buffer, pH 7.0). Reactions were
monitored by measuring the change in absorbance at 420 nm at 22° C.
Specific activity was defined a s nm oles ONPG hydrolysed p er minute per mg
soluble protein using th e formula:
(AOD42(}/min) (VT)
nmoles ONPG/min • mg =
((0.0045 cm -1 ml nmol*1)(V/v)([protein])(1 cm)
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W here: AOD42o/min = change in absorbance at 420 nm/ minute
VT = total assay volume (ml)
0.0045 cm -1 ml nmol' 1 is the extinction coefficient of ONPG62
V a = volume of soluble protein extract (pi)
[protein] = protein concentration in mg/pl
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Protein a ssa y s were performed by the method of Lowry

or using the BCA

reagents of Pierce Chemical using bovine serum albumin a s the standard.
Affinity Purification of B-Galactosidase Fusion Proteins. The synthesis
and u se of Sepharose-p-aminophenyl-1-thio-B-D-galactopyranoside in the
purification of B-galactosidase fusion proteins w as conducted according to the
method of Ullmann . E. coli extracts were prepared a s described above
except that lysis w as conducted in column application buffer (20 mM Tris, pH
7 .4 ,1 .6 M NaCI, 10 mM MgCl2).
Antibodies. Polyclonal rabbit anti-B-galactosidase antibodies were
purchased from Cooper Biomedical, Inc. Malvern, PA. Anti-ADR1 polyclonal
rabbit antibodies were kindly produced by Michael Morgan in the Denis
laboratory by immunization of rabbits with a synthetic peptide corresponding to
amino acid residues 208-231 of ADR1 and will be described elsewhere.
Immunoorecioitations. ADR1/B-galactosidase fusion proteins were
precipitated from E. coli extracts using anti-B-galactosidase antibodies under
native conditions a s previously described16.
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Precipitation of fusion proteins

under denaturing conditions using anti-ADR1 antibodies w as performed
essentially a s described65.
In Vitro PhosDhorvlationUsina_Bovine cAMP-Deoendent Protein

Kinase. E, coli extracts were phosphorylated using the catalytic subunit of
bovine cAMP-dependent protein kinase (Sigma P2645) in 10 mM Tris, pH 7.4,
4 mM MgCl2, 3 mM B-mercaptoethanol, 2 mM MnCl2 , 1 mM EDTA, 40 nM ATP,
2.6 X 10® cpm/pmol [y-32p] ATP. The am ount of kinase used is given in
picomolar units (pmol U) a s defined by Sigm a (1 pmol U is defined a s the
am ount of enzym e required to transfer 1.0 pmol of phosphate from [y -32p] ATP
to hydrolyzed and partially dephosphorylated casein per minute at pH 6.5 at 30°
C.) In experim ents where the kinase concentration w as varied the ATP
concentration w a s increased to 0.1 mM (2500 cpm/pmol [y -32p] ATP) such
that it would not be limiting. Reactions w ere allowed to proceed for 10 minutes
at 22° C. and w ere terminated by the addition of 5X SD S sam ple buffer
followed immediately by immersion in a boiling water bath for three minutes.
33

Autoradiography of SDS polyacrylamide gels w as a s previously described .
In Vitro Phosphorylation Using Ye a s t cAMP-Deoendent Protein Kinase

Purified catalytic subunit of the yeast cAMP-dependent protein kinase
encoded by the TPK1 gene w as the kind gift of Mark Zoller of Cold Spring
Harbor Laboratory. Reactions were carried out using the protocol of
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Roskowski . Reaction mixtures contained E. coli extracts, 50 mM MOPS (pH
7.0), 10 mM MgCI2 , 0.1 mM ATP (1000 cpm/pmol [y -32p] ATP), and 1.9 pg/ml
purified C 1 kinase in 50 |il reaction volumes. Reactions were carried out and
analyzed in a m anner analogous to reactions using the bovine kinase
described above.
Peptide Mapping of the ADR1 Phosphorylation Site

Protein extracts

containing the ADR1/ and ADR1c/6-galactosidase fusion proteins were
phosphorylated in vitro and separated by SDS-polyacrylamide gel
electrophoresis a s described above. The phosphoproteins of interest were
localized by autoradiography and excised from the dried gel. Chymotryptic
digestion of the 17 7 ,1 7 5 KDa doublet and the 164 KDa single fusion protein
w as performed essentially a s described by K aress and H anafuss67. Gel slices
containing either the 177,175 KDa doublet or the 164 KDa fusion protein
sp ecies were w ashed 4X for 15 minutes in 10% methanol at room tem perature
and lyophilized. Dried gel slices were treated with performic acid (performic
acid w as prepared by mixing one part 30% H20 2 with nine parts 90% formic
acid followed by incubation on ice for one hour) for one hour on ice, washed
twice with 1 ml water, and lyophilized. Dried performic acid-treated gel slices
were then neutralized by washing 2X for five m inutes with 1 ml 50 mM
NH4 HCO3 after which slices were w ashed with 1 ml w ater and lyophilized. The
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resulting dried gel slices were incubated with 0.75 ml chymotrypsin (Sigma, 0.1
mg/ml in 50 mM NH4HCO3) at 37° C for 15 hours. Peptides were eluted from
the gel slices with 0.9 ml of water by shaking end-over-end for 12 hours at 4° C.
The elution procedure w as repeated once and the combined supernatants were
lyophilized. The resulting sam ples were then redissolved in 0.1 ml 50 mM
NH4 HCO3 and redigested with 0.1 ml chymotrypsin for 6 hours. NH4HCO3
was once again rem oved by lyophilization and the dried sam ples were
resuspended in peptide-mapping sam ple buffer (1 M acetic acid, 0.05 M
NH4OH, 8 M urea).
The chemically synthesized peptide Leu-Lys-Lys-Leu-Thr-Arg-Arg-Ala-SerPhe, representing ADR1 amino acid sequence 222-231, w as used a s a
standard in the peptide mapping experiment.

This peptide w as phosphorylated

in vitro using bovine cAM P-dependent protein kinase in a m anner analogous

to the method described for labeling the E. coli extracts. The labeled peptide
w as purified on a Sephadex G-15 column in 0.05 M NH4HCO3 . Fractions
containing the phosphopeptide w ere identified by electrophoresis on a 50%
6fl

polyacrylamide gel a s described by W est and Bonner . Fractions containing
phosphorylated peptide were lyophilized and an aliquot w as removed for
treatm ent with chymotrypsin. Chymotrypsin digestion of the synthetic peptide
w as performed in parallel with digestions of proteins contained in the gel slices
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a s described above. A phosphorylation mix lacking a peptide or ADR1/Bgalactosidase fusion protein substrate was also digested in parallel a s a
control.
Final analysis of the phosphorylated peptides w as conducted using th e 50%
pH 3 polyacrylamide gel electrophoresis system described by W est and
68

Bonner . Gels were dried and phosphorylated peptides w ere visualized by
autoradiography.
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III. Results
Expression of ADR1/B-Galactosidase fusion protein in Yeast. Expression of
ADR1 in S. cerevisiae w as accomplished using plasmids in which fragm ents of
the ADR1 gene were ligated to the lacZ gene which codes for B-galactosidase.
The ADRl/lacZ fragm ents were placed under the control of the glyceraldehyde3-phosphate dehydrogenase (G3PDH) promoter
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and inserted into the yeast

plasmid vector YRp7. The G3PDH promoter w as chosen for its efficiency in
promoting transcription; G3PDH mRNA normally accounts for 2-5% of the total
y east poly A mRNA70. T hese expression plasmids were therefore expected to
produce high levels of ADR 1/B-galactosidase fusion protein. Fusion proteins
were predicted to be bifunctional, having both ADR1 acivity and Bgalactosidase activity. B-Galactosidase activities w ere to be a m easure of the
am ount of ADR1 /B-galactosidase fusion protein, while ADH II enzym e activity
w as predicted to provide an accurate m easure of the am ount of functional ADR1
protein present. Denis has shown that under glucose growth conditions the
level of ADH II activity is directly proportional to the ADR1 or ADR1-5C gene
d o sa g e 33. Due to possible problems with degradation or stability of the ADR1
portion of the fusion proteins, 8-galactosidase activities may be a less reliable
m easure of the am ount of functional ADR1 produced than is ADH II enzyme
activity.
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Two yeast ADR 1/G-galactosidase expression plasmids were used. The first
plasmid, JC1Z, contains DNA sequences encoding the N-terminal 304 amino
acids of ADR1 fused in frame to eigth codon of lacZ (Figure 3). The second
y east expression plasmid, JC25, contains seq u en ces coding for a larger fusion
protein containing 658 ADR1 amino acids fused to the sixth codon of lacZ
(Figure 4).
T h ese plasmids were transformed into yeast strain 500-16 fa d rl-1 . tro ll and
the expression of plasmid-encoded fusion proteins w as tested by growing cells
on com plete medium lacking tryptophan which had been supplem ented with
the chrom ogenic 6-galactosidase substrate X-Gal. The formation of small
colonies that were deep blue in color.confirmed that fusion proteins with 13galactosidase activity were being expressed. Plasmid-bearing cells grew very
slowly relative to plasmid-free controls. In addition, expression plasmids were
poorly maintained, even under selective growth conditions. This su g g ests that
ADR1 / 6-galactosidase overexpression may be toxic to the cell.
The level of ADR 1/ 6-galactosidase fusion protein expression w a s m easured
by assaying transform ants for 6-galactosidase and ADH II under various
selective growth conditions (Table 3). Cells containing plasmid w ere selected
for by growth in rich medium lacking tryptophan, by growth in the presence of
the respiratory inhibitor antimycin A, or by using cells which had spontaneously

Figure 3
C on struction of Y east A D R I/B -G alactosidase E xp ression Plasm id
JC1Z
ADR1 seq u en ces used in the construction of plasmid JC1Z were derived
from plasmids YRp7-ADR1-311ABcl and J S 1 19, both of which are described in
Materials and Methods. The Bam Hl-Bcl I fragment of JS 1 19 containing the
G3PDH promoter an d the first 440 nucleotides of the ADR1 coding sequence
w as ligated into the unique Bel I site of YRp7-ADR1-311ABcl to create plasmid
JC 1 . JC1 was cut a t the unique Bam HI site at +907 and ligated into plasmid
pSK S10556 at the Bam HI site in the polylinker. The resulting plasmid, JC1Z,
en co d es a fusion protein containing the 304 N-terminal ADR1 residues fused to
the seventh amino acid of B-galactosidase. Expression of the ADR1/iacZ gen e
fusion is controlled by the G3PDH promoter and the plasmid is selectable on
medium lacking tryptophan when present in a y east strain containing the trp1
allele.
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Figure 3: Plasmid JC1Z Construction
A m pr
Bam HI

Bell

Yeast G3PDH
Promoter

S'-ADR1
Bam HI

i

Figure 4
C onstruction o f Yeast A D R 1/Q -G alactosidase E xp ression Plasm id
JC 25
Plasmid JC 25 w as constructed by inserting the 8.6 kb Bam Hl-Sal I fragment
from JC100Z (described in Figure 5) into yeast vector YRp7. The final JC 25
construct contains codons for amino acids 1 to 658 of ADR1 fused in frame to
th e sixth codon of the lacZ' gene.
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Figure 4: Plasmid JC25 Construction
Ncol

Amp r
Hind III

JC 100Z
Bam HI

12.2 kb

lazZ

JC100Z
Bam Hl-Sal I fragment
into yeast vector YRp7

Trp
Bam HI
Amp

Y east G3PDH Promoter

ADfil

JC 25
14.0 kb

Sail

Hind III

LaQZ
LacY
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Table 3 .

A D R 1/B-G alactosldase F u sion Protein E xp ression In Y east

a ' nm oles ONPG hydrolysed per minute per mg soluble protein. All assay
values are the average of a minimum of three separate determinations.
k pm oles NADH oxidized per minute per mg soluble protein.
c“ Y east strain 500-16 fadrl -1) containing no plasmid a s determined by Bemis
and Denis23. All strains assayed except ADR1-304 are isogenic to strain
500-16.
■ YEP medium contains 2% w/v bactopeptone, 1% w/v yeast extract, 20 mg/L
adenine and uracil and w as supplem ented with either 8% glucose (YEPGlc) or 3% ethanol (YEP-EtOH).
e ‘ Trp- medium contained 6.7 g/l yeast nitrogen b ase, 20 mg/ml adenine,
uracil, and tyrosine, 5 g/L casam ino acids, and 10 ml/L Trp dropout solution
(0.5 g valine, 0.5 g threonine, 0.6 g phenylalanine, 0.2 g methionine, 0.4 g
lysine, 0.6 g leucine, 0.6 g isoleucine, 0.2 g histidine, and 0.2 g arginine in
100 ml water) and w as supplem ented with either 8% glucose (Trp-GIc) or
3% ethanol (Trp-EtOH).
f'

YEP medium containing 8% glucose and 0.6 pg/ml antimycin A.

y ‘ A ssay values a s determined by Bemis and Denis

for strain 500-16

carrying a plasmid which encodes the N-terminal 642 amino acids of ADR1
under the control of the ADR1 promoter. Values are shown for strains
carrying either a single integrated plasmid copy or free plasmid a s indicated.
h' A ssay values a s determ ined by Denis and Young24 for strain 500-16
carrying a plasmid which encodes the N-terminal 304 amino acids of ADR1
under the control of the ADR1 promoter. Values are shown for strains
carrying either a single integrated plasmid copy or free plasmid a s indicated.

37

T able 3.

A D R 1/8-G alactosidase Fusion Protein E xp ression In Y east

ADHII

fl-aalactosidase
p la sm id

activity fU/mgla
GiC

EtOH

none
4.1

activity fmU/mgl*3 cultu re
Glc

EtOH conditions

2

10

YEP

170

350

Trp-e

JC 2 5

1.4

JC 2 5

13

1600

YEP-Glc+At

JC 2 5 p

13

1470

YEP-GIc

8

ADR1-642 (integrant)9

1400

JC 1Z

2.3

JC1Z

4.5

30

1.4

390

70

ADR1-304 (integrant/

5

ADR1-304 (plasmid)11

100

38

YEP
YEP-Glc+At

530

ADR1-642 (plasmid)9

f

TrpYEP-Glc+At

800

YEP
YEP-Glc+At

becom e respiration deficient due to irreversible mitochondrial petite mutation.
Petite cells and cells grown in the presence of antimycin A must ferment
glucose to obtain energy. ADH II is required for fermentation in th ese cells
since the yeast strain transformed lacks th e fermentative isozyme ADH I.
B ecause ADR1 is required for ADH II production, petite cells or cells grown in
th e presence of antimycin A must maintain ADR 1-expressing plasmid to survive.
Respiration deficient cells bearing plasmid JC25, w hether petite or grown in the
presence of antimycin A, had ADH II and 13-galactosidase activities 9-fold
greater than found in cells grown in tryptophan-deficient medium. Plasmid
JC1Z-induced ADH II and 13-galactosidase activities w ere 2-fold higher in cells
grown in the presence of antimycin A than found in cells grown in tryptophandeficient medium. (3-galactosidase and ADH II activities therefore indicate that
respiration deficient cells selected more strongly for plasmids JC 25 and JC 1Z
than did cells grown on medium lacking tryptophan.
It should also be noted in Table 3 that under glucose growth conditions there
w as a direct correlation between 13-galactosidase activity and ADH II activity. In
strains carrying JC25, the ratio of ADH II activity to 13-galactosidase activity
(m ll/ll) is approximately 120 mll/U, while in JC 1Z -strainsthe ratio is 14 mU/U.
T h ese data indicate that under glucose growth conditions 13-galactosidase
activity provides a good m easure of the amount of functional ADR 1/0-
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galactosidase activity. Furthermore, it also indicates that the smaller J C 1Zencoded fusion protein has approximately one-ninth the transcriptional
activation activity (or ADR1 activity) of the JC25-encoded fusion protein,
assum ing that th e respective fusion proteins have similar 13-galactosidase
activities and are not differentially degraded by the cell. The efficiency of fusion
protein expression w as therefore m easured by comparison of the ADH II
activities of cells bearing plasmids JC25 or JC 1Z to cells bearing plasm ids with
similar-sized ADR1 truncations under the control of the ADR1 promoter.
The ADH II activity of strain 500-16 carrying plasmid JC 25 can be compared
to th e ADH II activity of the sam e strain carrying ADR1-642, a plasmid
constructed by Bemis and Denis23, when plasmids are maintained by growth in
th e presence of th e respiratory inhibitor antimycin A (At). Plasmid ADR1-642
contains a truncated ADR1 g en e encoding the N-terminal 642 amino acids of
ADR1 under the control of the ADR1 promoter. JC 25 w as designed to produce
an ADR1/8-galactosidase fusion protein containing 659 N-terminal residues of
ADR1. Comparison of ADH II activities in cells rendered respiration deficient
indicates that JC 25 produces about 3-fold more ADR1 activity than d o es the
ADR1-642 plasmid. Similarly,the ADH II activities of cells carrying plasmid
ADR1-30424 can b e com pared to cells carrying JC1Z since both plasmids
contain ADR1 se q u en c es coding for the N-terminal 304 amino acids of ADR1.
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500-16/JC1Z ADH II activities were found to be 0.7-fold that of the ADH II activity
of 500-16/ADR1 -304 when cells are grown in the presence of antimycin A.
Therefore under conditions which maximize expression, the JC1Z plasmid
ex p resses slightly less active ADR1 protein than com parable plasmids with
ADR1 promoters, while the JC 25 plasmid expresses more. This indicated that
the expression or stability of the J C 1Z protein, unlike its JC 25 counterpart, is
adversely affected by the fusion with 13-galactosidase under glucose growth
conditions.
Under ethanol growth conditions the ADH II activity in strains carrying
plasmid JC25 rose 90 milliunits per unit of 13-galactosidase, while the ADH II
activity in strains carrying plasmid JC1Z rose 280 milliunits per unit of 8galactosidase. Thus the JC1Z w as a more efficient activator of ADH2
transcription under ethanol growth conditions than under glucose growth
conditions (mU ADH ll/U 8-gal = 13 for glucose, 280 for ethanol). JC25encoded fusion protein, on the other hand, w as slightly less efficient on ethanol
than on glucose (mU ADH ll/U 8-gal = 120 for glucose, 90 for ethanol).
Furthermore, derepressed ADH II activites in strains carrying plasmids were
significantly less than strains expected to express similar sized ADR1 proteins
from truncated ADR1 g en es integrated in th e genom e (compare JC 25 and
JC1Z activities to ADR1-642 and ADR1-304 integrant activities under ethanol
growth conditions).
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Despite the fact that the ADH II activities of strains bearing plasmid JC25 or
JC1Z grown under derepressing conditions were much lower than expected,
ADH2 w as still significantly derepressed. In the c ase of JC1Z, 13-galactosidase
activities indicated that approximately three-fifths a s much fusion protein was
m ade under ethanol growth conditions a s under glucose growth conditions, yet
ADH II activity w as derepressed 13-fold. JC25 gave about a 3-fold
derepression of ADH2 and B-galactosidase activities indicated that there was
2.9-fold more fusion protein present under ethanol growth conditions. This
discrepancy in correlating (3-galactosidase activities with ADH II derepression is
thought to be an artifact which aro se due to the extremely poor growth of cells
bearing plasmid JC 25 when grown in ethanol containing medium.
Attempts to detect plasmid-encoded ADR1/13-galactosidase fusion protein in
yeast extracts were unsuccessful (data not shown). Silver staining of SDSpolyacrylamide gel lanes containing anti-B-galactosidase antibody precipitates
and yeast extracts failed to detect the presence of any proteins unique to
plasmid-bearing cells. Assuming that ADR1/0-galactosidase fusion proteins
have specific activities com parable to purified 13-galactosidase (purified 0galactosidase has a specific activity of 3 X 105 U/mg62), fusion proteins were
estim ated to account for approximately 0.004% of the soluble protein in
respiratory deficient strains bearing plasmid JC25. This estim ate may be low a s
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num erous 13-galactosidase fusion proteins have been shown to have specific
activities significantly lower than wild-type 13-galactosidase .
Expression of ADR1/ and ADRjC/B-Galactosidase Fusion Proteins in E. coli.
Plasm ids containing portions of the ADR1 coding sequence were ligated in
frame to the lacZ* gene and placed under the control of the la c promoter. The

lac promoter w as constructed by de Boer and coworkers71 by fusion of the E.
coli lcc "-35" (T-T-G-A-C-A) and lac UV-5 Pribnow box (T-A-T-A-A-T) promoter

regions. Transcription from this extremely efficient synthetic hybrid promoter is
repressed by the lac repressor and can be derepressed by the addition of the
fortuitous inducer isopropyl thiogalactoside (IPTG).
Two constructs, JC200Z and p6a45 (Figures 5 and 6), were used to
produce ADR1/B-galactosidase fusion proteins in E. coli. Plasmid JC200Z
w as predicted to produce a fusion protein of 191 KDa containing the N-terminal
659 amino acids of ADR1 fused to the eighth amino acid of B-galactosidase.
Plasmid p6a45 w as designed to produce a slightly sm aller fusion protein of 187
KDa and containing ADR1-5C protein seq u en ces from amino acid 17 to 642.
E. coli strains M182 (lac~) and RR1 (lac+) were transform ed with plasmid

6a45 or JC200Z. Cells bearing either expression plasmid appeared red and
w ere distinguishable from yellow control strains when exam ined 12 to 20 hours
after plating on MacConkey-lactose indicator plates containing ampicillin.
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Figure 5
C onstruction o f E. co ll ADR1/ and ADR1c /B -G alactosid ase
E xp ression P lasm id s in the JC200Z S eries
ADR1 sequence derived from plasmid JS 1 19 w as used in the construction
of JC200Z. A 2.4 kb BamHI- Hindll fragment of J S 1 19 encom passing ADR1
seq u en ces from +1 to +1971 w as inserted into the polytinker of E. coli vector
pUC19 to create plasmid JC100. A 1.9 kb Hinc ll-Hind 111 fragment containing
ADR1 coding seq u en ces from +48 to +1971 was removed from JC 100 and
replaced with a 622 bp Hinc ll-Hind III fragment from pBR322 to create plasmid
JCO. This "stuffer" DNA w as inserted to eliminate contamination of ligation
reactions with ADR1 seq u en ces during subsequent introduction of ADR1C
sequences. JC102, JC105, and JC 107 were then created by replacing the
stuffer DNA in JCO with 1.9 kb Hinc ll-Hind III fragm ents from plasm ids YRp7ADR1 -2°, YRp7-ADR1 -5C, and YRp7-ADR1 -7© respectively. A 2.4 kb BamHIHindll fragment of JC 100, JC102, JC 105, or JC107 encom passing ADR1 or
ADR1C seq u en ces from +1 to +1971 w as inserted into the polylinker of
pSKSIOS56 to create in-frame ADR 1-lac Z' fusions in JC100Z, JC102Z, JC105Z,
or JC107Z. An 8 kb Nco l-Nco I fragment from the start of ADR1 to the end of
the lac operon w as isolated from th e se plasmids an d inserted into pKK2401155 at a unique Nco I site downstream from the ta c promoter. T he final JC200Z
series constructs contain codons for amino acids 1 to 658 of ADR1 or ADR1C
fused in frame to the sixth codon of th e lac Z gene.
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Figure 5:JC200Z S eries Plasm id C onstructions
Bam HI

Nco I
Hinc II

Ampr

Insert 2.4 kb JS119 Bam Mi-Hind III
fragment into
E. coli vector pUC19

JC 100
ADR1

5.1 kb

Hind III

Replace ADR1 Hinc ll-Hind III fragment
with pBR322 "stuffer" DNA

Ampr

Hinc II
Stuffer DNA

Replace "stuffer" DNA with
ADR1c Hincll-Hindll fragment
Bam HI

Nco I
Hinc II

Figure 5 (continued)

NCO I

APR1 or ADR1
Insert Bam Hl-Hind III
fragment from
JC 100 series plasm ids into
pSKS105

Hindi

►

JC 100Z
JC102Z, JC 105Z, JC107Z

12.2 kb
L acZ

Nco I

LSQX'
Insert Nco I fragm ent of JC100Z series plasmids
into pKK240-11

Nco I

Amp
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JC 200Z
JC202Z, JC205Z, JC207Z
12.7 kb

Nco I
ADR1
or

AQBI
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Figure 6
C onstruction o f

E. coll

ADR1-5c /8 -G a la cto sId a se E xp ression
P lasm id 6a45

For plasmid p6a45 the Hinc ll-Bam HI 3.2 kb fragment of plasmid YRp7ADR1-5C-23A16 w as ligated into plasmid pKK240-1155 at the Hind III site after
both fragm ents had been rendered blunt-ended using th e Kienow fragment of
E. coli polymerase I. The unique Hind III site in plasmid pKK240-11 is situated
such that a tag promoter, an ATG start codon, and two additional codons were
fused in frame to the 17th codon of ADR.1-50 upon ligation. This plasmid,
designated p6a, w as then digested with Bgl II and Bam HI and the resulting 2.1
kb fragment containing the tac promoter and a portion of the ADR1-5C gene
w as ligated into the Bam HI site of lacZ vector PRB4554. The final construct,
p6a45, contains codons for amino acids 17-642 of ADR1-5C fused in-frame to
the lac Z gene at codon eight.

The nucleotide sequence of the pKK240-11/

ADR 1-5° junction is shown the lower right corner.
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Figure 6: C onstruction of nlaemld 6a45
(Bam Hl/Hind III)

Amp^
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Som e cells were observed to lose the ability to express B-galactosidase after
repeated plating a s indicated by their inability to produce the characteristic red
bile salts. This result w as interpreted to be indicative of plasmid loss or
mutation; cells which had lost their ability to yield red colonies w ere discarded.
Extracts of cells containing plasmid p6a45 and JC200Z were prepared and
assay ed for B-galactosidase activity a s described in Materials and Methods. E.
coli plasmids w ere found to express significantly more B-galactosidase activity

than com parable yeast plasmids (Table 4). JC200Z, which is predicted to
produce a fusion protein identical to that produced by th e yeast vector JC25,
expressed approximately 300 fold more B-galactosidase activity th an its yeast
counterpart. E. coli fusion proteins were estim ated to account for 1 -2% of the
total soluble protein in the E. coli cell extracts. Fusion protein production was
found to be relatively insensitive to the strain differences.
Detection of Fusion Proteins Produced bv Plasm ids JC200Z an d 6a45.
Protein extracts from plasmid-bearing cells were fractionated on SD Spolyacrylamide gels and stained for protein (Figure 7a). Protein extracts
derived from E coli carrying plasmid JC200Z contained five discrete fusion
proteins which w ere unique to plasmid-bearing cells. T hese proteins had
relative molecular weights of 1 8 2 ,1 7 7 ,1 7 5 ,1 6 4 , and 122 KDa. The size of the
largest fusion protein detected, 182 KDa, is in approximate agreem ent with the
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Table 4
B-G alactosldase Activities of ADR1 /(VGalactosidase Fusion
Proteins Expressed in

olasmid

strain

E. coll

B-galactosidase activity
(U/mg)a

RR1(lac+)

5

p6 a4 5

RR1(lac+)

5000

JC 200Z

RR1(lac+)

3500

4562(lac‘)

0

p 6 a4 5

4562(lac')

4900

JC 200Z

4562(lac*)

4400

a nmoles ONPG hydrolysed per minute per mg soluble protein.
62

Assays w ere performed essentially a s described by Miller . All assay
values are the average of a minimum of three separate determinations. Cells to
be assay ed w ere grown at 37° C overnight in L-broth supplem ented with 50
pg/ml ampiciilin and were lysed at 0° C by sonication in buffer A:200 ( 25 mM
HEPES, pH 7 .5 ,5 mM MgCl2 , 1 mM EDTA, 5 mM 6-m ercaptoethanol, 1 mM
phenylmethylsulfonyl chloride, 2 |iM pepstatin, 0.6 pM leupeptin, 200 mM KCI).
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predicted size of 190 KDa for the full-length JC200Z fusion protein. The 182,
1 7 7 ,1 7 5 , and 164 KDa fusions appear to be present at approximately equal
concentrations, while the 122 KDa species is significantly more abundant than
the other fusions. Densitometric quantitation of the 122 KDa species relative to
the higher molecular weight fusions w as impeded by negative staining of this
protein on silver-stained gels.
The four truncated fusion proteins sm aller than 182 KDa could have been
the result of transcription or translation initiation from within the ADR1 coding
seq u en ce or of specific proteolysis of the full-length fusion protein. S ea rc h es
for prokaryotic prom oter elem ents72 or ribosome binding sites (Shine-Delgamo
se q u e n c e s)73 within ADR1 revealed no such homologies. If the truncations
were the result of specific proteolysis, the degradation m ust have occurred
within the cell prior to lysis since cells lysed by boiling in SDS-sample buffer
produced the sam e gel pattern a s cells lysed by sonication in the a b se n c e of
protease inhibitors (data not shown).
Plasmid p6a45 w as observed to produce a pattern of five discrete fusion
protein products similar to that obtained with JC200Z (Figure 7a). The largest of
th ese, presumably the full-length fusion protein, had a slightly greater mobility
than th e full-length JC200Z fusion protein. This was consistent with the
predicted difference in molecular weight betw een the two p ro tein s, a s JC200Z

Figure 7.

D etection of A D R 1/B-G alactosidase F usion P roteins in

a . Identification of A D R 1/B -galactosidase fusion p rotein s.

E. coll

Silver-

stained SDS-polyacry!amide gel of extracts from E coli containing either the
control plasmid pKK240-11, plasmid JC200Z, or plasmid p6a45.

Numbers at

the left of the gel refer to molecular weights of marker proteins in KDa,
arrow heads indicate plasm id-encoded fusion proteins with calculated
molecular weights of 182,177, 175,164, and 122 KDa for JC200Z and 180,
175 (two comigrating proteins), 162, and 120 KDa for p6a45. The gel w as
stained with Gelcode silver stain (Pierce Chemical Co., Rockford, IL)
b. In vitro p h osp h orylation of A D R 1/B -galactosidase fu sio n
proteins. Autoradiogram of the gel pictured in a. showing fusion proteins
phosphorylated by bovine cAMP-dependent protein kinase in vitro. Reactions
w ere performed a s described in Materials and Methods with bovine cAPK at a
concentration of 1 pmol U/pl.
d. Precipitation o f phosp horylated fu sio n proteins u sin g anti-ADR1
an tib od ies. Antibodies raised against a synthetic peptide containing ADR1
amino acids 208-231 were used to precipitate ADR1-containing fusion proteins
from denatured extracts of E. coli strain M182 carrying the plasmid indicated at
the top of each lane.
d.

Precipitation of phosphorylated fu sio n proteins u sin g anti-B-

g a la cto sid a se antib odies. Autoradiogram of whole extracts and anti-8galactosidase antibody precipitates of extracts of E coli strain RR1 carrying
no plasmid (controls) or plasmid p6a45.

p K K 2 4 0 -1 1
JC 200Z
p6a45

p K K 240-11
JC 200Z
p6a45
p K K 240-11
JC 200Z
p6a45

,'v;

n o p lasm id
n o p la sm id +
p6a45
p 6 a 4 5 + Ab

w as predicted to produce a 190 KDa protein while p6a45 w as predicted to
produce a 186 KDa protein. With the possible exception of the 122 KDa
species, the truncated products of p6a45 also appear to be slightly reduced in
size when com pared to their JC200Z counterparts.
The fusion proteins in extracts of E.coli strain M182 (la c ) carrying plasmid
p6a45 were partially purified on a sepharose-p-aminophenyl-1-thio-8-Dgalactopyranoside B-galactosidase affinity column. P eak fractions were
inspected for fusion proteins using SDS-PAGE (Figure 8). The elution fraction
having the highest B-galactosidase activity also contained num erous proteins
which were presum ably bound non-specifically to the affinity resin despite the
u se of the high-volume, high-stringency washing procedure of Ullmann (100
column volumes with 1.6 M NaCi in phosphate buffer). Of the identified fusion
proteins, only the 122 KDa fusion protein species appeared to be significantly
enriched (Figure 8 ; com pare p6a45 lane to ACF lane). This fusion protein,
which is in the greatest abundance of all the fusion proteins in crude extracts,
must therefore have B-galactosidase activity. While the other fusion species
may also have activity, their affinity to the column may be detrimentally affected
by the presence of the N-terminal ADR1 sequences. It is unlikely that the
abundant 122 KDa species sterically excluded the other fusion proteins from
binding to the resin a s the column w as significantly under-loaded (see Figure 8

54

Figure 8
SDS-PAGE of 8-G alactosid ase Affinity Colum n Peak Fraction
P r o te in s
Silver stained SDS-polyacrylamide gel analysis of affinity purified fusion
proteins encoded by plasmid p6a45 in E. coli strain M182 (lane designated
ACF for Affinity Column Eraction). Reference lanes contain extracts of strain
M182 bearing no plasmid or plasmid p6a45, a s indicated. Numbers to the left
of the gel indicate the mobilities of marker proteins with molecular weights in
KDa. The arrow head on the right indicates the 122 KDa fusion protein, a s
discussed in the text.
Approximately 2 mg of soluble protein containing 8800 units of 8galactosidase activity w as applied to a 1 ml 8-galactosidase affinity column
(capacity estim ated to be 84,000 units) prepared according to Ullmann64. The
column w as w ashed with 100 column volumes of high-salt wash buffer to
rem ove non-specifically bound proteins. Proteins having 8-galactosidase
activity were eluted from the column with 100 mM sodium borate, pH 1 0 ,1 0 mM
8-m ercaptoethanol. 0.5 ml fractions were collected and assayed essentially a s
described

eo

. The second and third fractions were found to contain -8 0 % of the

activity loaded and represented an approximately 7-fold purification. Peak
fractions were pooled and concentrated and an aliquot containing 15 pg of
protein w as applied to the gel. Reference lanes contain 100 pg of protein in
each lane.
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legend).
Extracts of E. coli bearing p6a45 were also analysed using native PAGE
followed by in situ activity staining for B-galactosidase (Figure 9). Only a single
diffuse band of B-galactosidase activity w as observed. This band w as excised
and re-fractionated using SOS-PAGE. The only active band observed w as
identified a s the 122 KDa fusion protein (Figure 9). Therefore, although all the
fusion proteins could have B-galactosidase activity, B-galactosidase activity w as
only detected in the 122 KDa species.
In Vitro Phosphorylation of ADR1/BGalactosida se Fusions Using Bovine

cAMP-Dependent Protein Kinase.

Extracts of E. coli bearing either plasmid

6a45 or JC200Z w ere phospho-labeled in vitro with ex cess bovine cAMPdependent protein kinase and [y-32p] ATP. The resultant radioactive proteins
w ere subjected to SDS-PAGE and detected by autoradiography (Figure 7b).
The JC200Z-encoded proteins of 1 8 2 ,1 7 7 ,1 7 5 , and 164 KDa w ere all
phosphorylated, a s were the corresponding p6a45 proteins. The 122 KDa
sp ecies, although the most abundant of the fusion proteins, w as not
phosphorylated. This species therefore appears to lack sufficient ADR1
residues to act a s a substrate for the protein kinase, a s discussed below.
Polyclonal antibodies directed against a synthetic peptide containing ADR1
residues 208-231 were used to precipitate the phosphorylated fusion proteins
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Figure 9
a . In S itu A ctivity S ta in in g of P ro te in s D isplaying B -G a la c to s ld a se
A ctivity.
Lanes contain approximately 300 pg of soluble protein from E. coli strain
M182 (lac*) bearing no plasmid, plasmid p6a t or p6a45 a s indicated. Purified
8-galactosidase w as purchased from Sigma; approximately 700 units were
applied (3 pg). Native PAGE and subsequent staining for 8-galactosidase were
performed a s described in Materials and Methods.
b.

SD S-PA G E o f B -G a la c to sid a se A ctivity-C ontaining F u sio n
P ro te in s Iso la te d from a N ative P o ly acry lam id e Gel
C rude extracts of E. coli M182 bearing no plasmid or plasmid p6a45 were

run for reference in the first two lanes. The third lane contains the major band of
8-galactosidase activity in a . (NB). Numbers to the left of the gel refer to the
molecular weights of marker proteins in KDa. The 122 KDa fusion protein is
indicated by the arrowhead on the right.
After excision from the native gel, the band containing the p6a45 active band
w as soaked overnight in 10% acetic acid. The gel slice w as then w ashed twice
for one hour in 1X SDS sam ple buffer, decanted, and the gel slice w as placed
in a boiling w ater bath for 5 minutes prior to insertion into the sam ple well. The
SD S gel w as stained with the Gelcode stain of Pierce Chemical Co. (Rockford,
IL).
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purified 6-gal
n o plasm id
p 6a
p6a45

200
n o plasm id
6a45
NB

encoded by plasmids p6a45 and JC200Z (Figure 7c).

The 182,177, and 175

KDa fusion proteins were all specifically precipitated by this antibody. The
analogous proteins from the p6a45 extract were also observed to be
immunoprecipitated. The 164 KDa fusion protein produced by either JC200Z or
p6a45 w as not immunoprecipitated by this antibody and therefore either d o e s
not contain sufficient ADR1 seq u en ces to be recognized by the antibody or folds
in such a way that interaction with the antibody is blocked. The 122 KDa
protein, which is not phosphorylated, w as also not visible in protein stains of the
anti-ADR1 antibody immunoprecipitates. T hese results indicate that the 122
KDa fusion protein d o e s not contain the ADR1 protein seq u en ces recognized
by cAPK or the anti-ADR1 antibodies.
A similar immunoprecipitation experiment w as conducted using a polyclonal
anti-8-galactosidase antibody. All fusion proteins expressed by p6a45, a s
evidenced by protein staining (Figure 10) and autoradiography (Figure 7d),
were observed to be immunoprecipitated. T hese results indicate that although
only the 1 8 2 ,1 7 7 ,1 7 5 and 164 KDa species were phosphorylated (Figure 7a),
all five fusion proteins contain sufficient B-galactosidase sequence to be
recognized by the anti-B-galactosidase antibody.
The approximate locations of the truncation sites resulting in the 122 KDa
and 164 KDa JC200Z-encoded fusion protein products were postulated by the
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Figure 10
SDS-PAGE A n a ly sis of p6a45-E ncoded P roteins P recipitated by
A nti-B -G alactosidase A ntibody
Silver stained SDS-polyacrylamide gel of anti-B-galactosidase antibody
precipitates from E. coii RR1 bearing no plasmid or plasmid p6a45. The right
hand lane contains crude p6a45/RR1 extract. Num bers to the left of the gel
indicate migration of molecular weight standards in KDa. The p6a45-encoded
122 KDa fusion protein is indicated on the right.
Antibody precipitations were carried out under native conditions using
polyclonal anti-IJ-galactosidase antibodies a s described in Materials and
Methods. The gel w as stained with th e Kodavue system (Eastm an Kodak,
Rochester, NY).
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following reasoning: The sm allest and most abundant fusion protein (122 KDa)
was not phosphorylated nor w as it precipitated by the anti-ADR1 antibody. It
was, however, precipitated by the anti-8-galactosidase antibody and in situ
activity staining indicated that it did have B-galactosidase activity. B ased on the
molecular weight derived from SDS-PAGE, the 122 KDa fusion protein w as
estim ated to contain 550 fewer amino acids than the full length fusion protein
which contains 659 ADR1 residues and 1017 B-galactosidase residues. The
122 KDa sp ecies therefore most likely contains only a small portion of ADR1
lacking the phosphorylation site at amino acid 230 fused to a whole o r near
whole functional B-galactosidase protein. The 164 KDa protein w as
phosphorylated, was precipitated by anti-B-galactosidase antibody, but was not
precipitated by the anti-ADR1 antibody. The truncation site in the 164 KDa
ADR1 /B-galactosidase fusion protein may lie between residues 208 an d 227 of
ADR1 in order for it not to be recognized by the anti-ADR1 antibody which is
directed specifically against the 208-231 ADR1 peptide, yet still retain th e ability
to be phosphorylated at serine-230. Results of peptide mapping experiments
discussed below indicate that phosphorylation of the 164 KDa fusion protein
occurs solely at residue 230. Alternatively, the SDS-PAGE derived molecular
weight indicates that the 164 KDa species lacks approximately 170 residues
indicating that cleavage may occur at a site to the N-terminal side of residue
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208, yet alter the folding of the resulting protein such that interaction with the
anti-ADR1 antibody is blocked.
Relative Phosphorylation of ADR1/ and A D R lC/B-Galactosidase Fusion
Proteins. Previous investigations hypothesized that ADR1 mutant proteins
which allow ADH2 expression to partially e sc a p e glucose repression are not
phosphorylated a s efficiently a s wild-type ADR1
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. This hypothesis w as tested

using plasm ids JC202Z, JC205Z, and JC207Z. T hese plasmids are identical to
plasmid JC200Z except they contain the ADR1-2C. ADR 1-5°. and ADR1-70
mutations, respectively (Figure 5). Extracts of E. coli bearing these plasmids
were phosphorylated using varying concentrations of bovine cAMP-dependent
protein kinase and analyzed by SDS-PAGE (Figure 11).
The ADR1-2C. ADR1-5C. and ADR1-7C mutations w ere found to significantly
d ecrease the level of fusion protein phosphorylation relative to wild-type ADR1.
This trend becam e progressively clearer a s th e level of kinase in the
phosphorylation mixes decreased (Figure 12).

In other words, at low kinase

concentrations the ADR1 protein w as a better substrate for cAPK and w as
phosphorylated to a greater extent than w ere the ADR1-2C, ADR1-50, and
ADR1-7C proteins. At higher kinase concentrations the ADR1-20 and ADR1-50
proteins appeared to be phosphorylated to nearly the sa m e extent a s the wildtype protein. Thus ADR1 mutations which render ADH2 expression constitutive
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Figure 11
R elative P hosp horylation of ADR1/, ADR1-26/, ADR1-5C/, and
A D R 1-7c /B -G alactosid ase F usion P rotein s U sing B ovin e cAMPD ependent Protein K inase
Autoradiogram of plasmid-bearing E. coli strain M182 extracts
phosphorylated in vitro using bovine cAM P-dependent protein kinase and
separated on a 5% SDS-polyacrylamide gel. Extracts of E. coli strain M182
bearing plasmids JC200Z (ADR1), JC202Z (ADR1-2C), JC205Z (ADR 1-5°), and
JC207Z (ADR1-7C) were prepared, phospho-labeled and fractionated on an
SDS-polyacrylamide gel a s described in Materials and Methods. The ATP
concentration w as 0.1 mM with a specific activity of 2.5 X 103 cpm/pmol and the
concentration of the catalytic subunit of bovine cAMP-dependent protein kinase
w as varied a s indicated.
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Figure 12
Graphical R epresentation of P h osp h ate Incorporation in th e
ADR1 C Fusion P rotein s Relative to the ADR1 Fusion P rotein s
Phosphate incorporation w as m easured by densitometric scanning and
integration of the 164 KDa fusion protein bands appearing on the
autoradiogram in Figure 11. Phosphate incorporation in each fusion protein
w as scaled to the amount of fusion protein present in each labeled band a s
determined by densitometric analysis of the silver stained polyacrylamide gel
The total am ount of phosphate incorporated into the ADR1/0-galactosidase
fusion proteins at the highest kinase concentration (0.14 pmol U/ pi) w as
arbitrarily scaled to 1. Each value for the indicated fusion protein sp ecies is
presented a s the fraction of that total.
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Figure 12a. 182 KDa Fusion Phosphorylation
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Figure 12b. 177,175 KDa Fusion Phosphorylation
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Figure 12c. 164 KDa Fusion Phosphorylation
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Figure 12d. Total Fusion Phosphorylation
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0.140

in y east also d e crea se in vitro phosphorylation of ADR1 by bovine cAMPdependent protein kinase. Since th ese mutations alter residues within the
phosphorylation consensus region found between amino acids 227 and 230,
the serine residue at amino acid 230 m ost likely serves a s the primary
phosphate acceptor of ADR1 cAMP-dependent phosphorylation.
The presence of a second ADR1 phosphorylation site w as indicated by the
phosphorylation of fusion proteins produced by plasmid JC207Z. This plasmid
carries the ADR1-7C mutation and therefore encodes a fusion protein in which
the phosphoacceptor serine at amino acid 230 is replaced by a leucine.
Although such a mutation would be expected to eliminate phosphorylation at
the primary site, it did not completely block phosphorylation of the fusion
proteins (Figure 11). The 182,177, and 175 KDa ADR1-7c/l3~galactosidase
fusion proteins w ere all slightly but significantly phosphorylated (Figs. 11 & 12).
However, even at high kinase concentrations, the 164 KDa fusion protein w as
not phosphorylated. It therefore appears that a secondary phosphorylation site
exists to the N-terminal side of the primary site at amino acid 230 which is not
present in the truncated 164 KDa protein. Phosphorylation of this secondary
site w as only detectable at high enzyme concentrations indicating that it is a
less "preferred" substrate for the cAMP-dependent protein kinase than the
primary site.
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Peptide Mapping of the ADR1 Phosphorylation Sites.

Phosphorylated

ADR1/ and ADR1c/l3-galactosidase fusion proteins were isolated from SDSpolyacrylamide gels and digested with chymotrypsin. The resulting peptides
were analyzed using native PAGE a s described in Materials and Methods
(Figure 14).
The 164 KDa fusion protein, the doublet containing the 177 and 175 KDa
species, and the 182 KDa fusion protein were each excised from lanes
containing JC200Z (ADR1), JC202Z (ADR1-20), JC205Z (ADR 1-5°) and
JC207Z (ADR1-70) extracts. The proteins contained in the 182 KDa and 177,
175 KDa doublet were thought to contain two phosphorylation sites, a primary
site at amino acid 230 and an unidentified secondary site, while the 164 KDa
protein apparently contained only the primary site. Comparison of labeled
peptides produced by digestion of th ese two protein species thus allowed
differentiation betw een those chymotryptic peptides containing the primary site
of phosphorylation and those containing the secondary site of phosphorylation.
A synthetic peptide spanning amino acids 222 to 231 of ADR1 w as
phosphorylated and electrophoresed on the mapping gel in both chymotrypsindigested and undigested form a s indicated in Figure 13. This peptide contained
the putative primary phosphorylation site at amino acid 230 and thus served a s
a standard for comparison to the ADR1 fusion protein digest. The undigested
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Figure 13
ADR1 Am ino Acid S e q u e n c e Surrounding th e Putative
P hosphorylation S ite at Amino Acid 230.
L, A D R 1-7®
A
K , A D R 1-5p

S , ADR1-2®

201
NRTTANTRR

k

k

The seq u en ce of the undigested synthetic peptide is boxed. Bold arrows
beneath the sequence indicate possible chymotryptic cleavage sites, circles
represent serine residues likely to serve a s phosphoacceptors b a sed on
homology to known sites of cAMP-dependent protein kinase recognition
sequences. Predicted alterations in primary structure c au se d by the ADR1C
mutations a re indicated above the single letter amino acid abbreviations. The
bold line beneath residues 226-231 indicates the presum ed limit digest product
of the ADR1/l3-galactosidase fusion containing the primary phosphorylation site.
T he ADR1-2C limit digest product w as predicted to contain residues 226-239
d u e to loss of th e chymotryptic site after phenylalanine3 3 1 . Calculated charge
to frictional coefficient ratios of the putative chymotryptic digest products are
approxim ated in calculations presented in Appendix D.
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Figure 14
P eptide Mapping of th e Primary P hosphorylation S ite in ADR1
Autoradiogram of a 50% polyacrylamide gel (pH 3) containing
phosphorylated peptides produced by chymotryptic digest of ADR1/Ggalactosidase fusion proteins a s described in Materials and Methods. Digests
of the 182 KDa fusions, the 177 and 175 KDa fusions, and the 164 KDa fusions
appear in the lanes indicated. The top of each lane is labelled according to the
ADR1 mutation it contains. Lanes containing digested and undigested synthetic
ADR1 peptide standards are so indicated and are described in Materials and
Methods. The Control lane contains a chymotrypsin-digested phosphorylation
mix which lacked a peptide or E. coli extract substrate.
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peptide, which w as designed a s a chymotryptic digest product, ran near the
front on th e mapping gel (Figure 14). After digestion its mobiiity decreased,
presumably a s the N-terminal four residues w ere removed to produce th e limit
digest product defined by residues 227-231.
Digestion of the ADR1/8-galactosidase fusion proteins in the 182,177 -175,
and 164 KDa bands revealed three major phospho-labeled peptides, the
slowest migrating of which co-migrated with the synthetic peptide limit digest, in
both the 177,175 KDa doublet and the 164 KDa species. The peptide with the
greatest mobility ap p ears faintly in the 164 KDa digest lane (Figure 14) a n d is
presum ed to be a partial digest product which contains the primary
phosphorylation site at serine-230. This conclusion is supported by the fact that
both the slowest and fastest migrating peptides of the ADR1 182 and 177-175
KDa digests are not present in the digests of the ADR1-7C 182 and 177-175
KDa fusion proteins. In contrast, the peptide having an intermediate mobility in
the ADR1 182 and 177-175 KDa digest lanes is present in all the ADR1C 182
and 177-175 KDa fusion protein digest lanes. B ecause th e ADR1 -7C fusion
protein cannot be phosphorylated at residue 230, this intermediate band must
be a peptide containing a secondary phosphorylation site. T he absence of this
intermediate-mobility peptide in all of the 164 KDa digest lanes indicates that it
is derived from se q u en ces on the N-terminal side of residue 230. It can b e
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concluded that under th ese conditions ADR1 is selectively phosphorylated at
two specific sites.
The ADR1-2C mutation, which eliminates the chymotryptic cleavage site at
amino acid 231, resulted in a d ecrease in the mobility of the partial and limit
digest phosphopeptides containing residue 230 due to the d ecreased charge
to frictional coefficient ratio caused by the extension of the peptide (see
Appendix D for th ese calculations). The ADR1-5C mutation, on the other hand,
cau sed an increase in the mobility of these phosphopeptides relative to the
ADR1 digest. Although the ADR1-50 mutation d o es not alter any chymotrypsin
sites directly, the change from an arginine to a lysine within the labeled
peptides apparently c au se s an alteration in mobility.

It should be noted that the

ADR1-2C partial digest peptide (having the greatest mobility) and the ADR1-5C
limit digest peptide (having the lowest mobility) both comigrated with the
peptide containing the secondary site. T hese ADR1-2C and ADR1-5C peptides
are present in the 164 KDa digest patterns further supporting that they are
derived from the peptide containing the primary site of phosphorylation. The
partial digest peptides containing residue 230 varied in their autoradiogram
signal intensity relative to the limit digest peptide from digest to digest,
supporting the conclusion that they result from partial proteolysis of the whole
fusion proteins. Chymotryptic digestion and peptide analysis of the 182 KDa
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ADR1/ and ADR10/ B-galactosidase fusion proteins gave similar mapping
results to the results obtained using the 177,175 KDa protein (Figure 14).
Unfortunately the ADR1-2C 182 KDa digest was lost during the procedure .
Phosphorylation of A D R1/and ADRIC/B-Galactosidase Fusion Proteins by
Y east cAMP-Deoendent Protein Kinase. Purified y e ast cAMP-dependent
protein kinase catalytic subunit C1 encoded by the TPK1 locus w a s also used to
phosphorylate the fusion proteins in vitro. The fusion proteins w ere
phosphorylated by yeast cAPK in a m anner similar to that observed with the
bovine kinase. As shown in Figure 15, the ADR1, ADR1-2C an d ADR1-50
fusion protein bands of 1 8 2 ,1 7 7 ,1 7 5 , and 164 KDa were labeled by the C1
kinase while th e ADR 1-7^ fusion band of 164 KDa was, a s se e n with the
bovine kinase, not phosphorylated. Phosphorylation was specifically blocked
by th e addition of purified yeast cAMP-dependent protein kinase regulatory
subunit (R encoded by BCY1 ).
Although th e yeast and bovine kinases were observed to phosphorylate th e
sa m e fusion protein species, the two enzym es w ere found to differ in their
apparent specificities for th e ADR1-2C and ADR1 -5C proteins. Using the bovine
kinase the relative incorporation of phosphate w as ADR1 > ADR1-5C > ADR1-2C
> ADR1-7C. In contrast the yeast kinase phosphorylated ADR1 > ADR1-20 >
ADR1-50 > ADR1-7C (Figure 16). On this basis it is concluded th a t yeast C1
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kinase phosphorylates the sequence RRASSS (ADR1-20) better than the
sequence RKASFS (ADR1-5C), while the mammalian kinase phosphorylates
the sequence RKASFS better than the sequence RRASSS. The two kinases
may therefore differ in their substrate specificities.
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Figure 15
R elative P h osp h orylation o f ADR1/, ADR1-20/, ADR1-50 /, and
A D R 1-7C /B -G alactosldase F usion P roteins U sing Y east cAMPD ependent Protein K inase C1
Autoradiogram of plasmid-bearing E. coli strain 4562 extracts
phosphorylated in vitro using the purified yeast kinase C1 a s described in
Materials and Methods.

In those lanes indicated (+) purified yeast regulatory

subunit R fB C Y l ) w as added to a concentration which w as 10 fold higher than
that of the catalytic subunit.
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Figure 16.

a.

S u b strate S p ecificities of th e Y east and B ovin e K in ases

Graphical rep resen tation of p h osp h ate incorporation in the 164

KDa ADR1/, ADR1-2C/, and ADR1-5c //ft-g a la c to sid a se fu sio n
protein s using y e a s t cAM P-dependent protein k in ase C1.

P h o s p h a te

incorporation w as m easured by densitometric scanning and integration of the
164 KDa fusion protein bands appearing on the autoradiogram in Figure 15.
Phosphate incorporation in each fusion protein w as scaled to the am ount of
fusion protein p resent in each labeled band a s determ ined by densitometric
analysis of the silver stained polyaciylamide gel. The total amount of
phosphate incorporated into the 1 8 2 ,1 7 7 ,1 7 5 , and 164 KDa ADR1/8galactosidase fusion proteins w as arbitrarily scaled to 1. The values for the
relative phosphorylation of the ADR1, ADR1-2C, and ADR1-50 fusion protein
sp ecies are presented a s the fraction of that total.

b.

Graphical rep resen tation o f p h osp h ate incorporation In th e 164

KDa ADR1/, ADR1-2®/, and ADR1-5c //B -g a la c to sid a se fu sio n
p rotein s using b ovin e cAM P>dependent protein kin ase.

E xpanded

graph of phosphate incorporation into the 164 KDa fusion protein by 0.003 pmol
U/fj.1 bovine kinase a s shown in Figure 11.
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IV. Discussion
In the model proposed by Denis and Gallo32 the glucose repression of
ADH2 is mediated in part by a glucose-dependent reduction in the activity of the
transcriptional activator ADR1. Based on the characterization of the ADR1 -5°
mutation, ADR1 activity w as proposed to be reduced during fermentative growth
a s a result of cAM P-dependent phosphorylation. The results of the work
presented herein strongly support the involvement of cAMP-dependent
phosphorylation in the regulation of ADR1 activity.
Using ADR1/3-galactosidase fusion proteins expressed in E coli it w as
dem onstrated that in vitro mammalian cAPK phosphorylates ADR1 at two
distinguishable sites. A phosphorylated chymotryptic peptide was found to
comigrate with a phosphorylated chymotryptic fragment derived from a synthetic
peptide containing ADR1 residues 227-231. The mobility of the labeled peptide
on a peptide mapping gel w as altered when it contained either the ADR1-2C or
ADR1-50 sequences. Other peptides presum ed to be partial chymotrypsin
digest products also displayed altered mobilities. Furthermore, when the
peptide contained ADR1-7C seq u en ces (in which the phosphoacceptor serine
at residue 230 is replaced by leucine), phosphorylation w as eliminated
(com pare phosphorylation of ADR1- and ADR1-7c-peptides in the 164 KDa
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d ig ests of Figure 14). T hese d a ta strongly indicates that mammalian cAPK
recognizes ADR1 residues 227-231, with serine-230 serving a s the
phosphoacceptor.
The results also indicate the existence of a second in vitro phosphorylation
site in ADR1 which is weakly recognized by yeast and bovine cAPK relative to
th e primary phosphorylation site at serine-230. The 182,177, and 175 KDa
ADR1 -7c/8-galactosidase fusion proteins w ere phosphorylated in vitro despite
the fact that in th e se mutant proteins the phosphoacceptor serine at residue 230
is replaced by a leucine residue. Furthermore, the 164 KDa ADR1/, ADR1-20/,
and ADR1-5c/f3-galactosidase fusion proteins were all phosphorylated in vitro,
while the ADR1-7C 164 KDa fusion protein w as not, indicating that the 164 KDa
fusions lack the secondary phosphorylation site. Finally, peptide mapping of
th e 182,177, and 175 KDa ADR1-7C/8-galactosidase fusion protein digests
revealed a single phosphorylated peptide which is present in digests of all the
com parable ADR1, ADR1-2C, and ADR1-5C fusion proteins. This peptide, which
w as not observed in the 164 KDa digests, is presum ed to encom pass a
secondary phosphorylation site in ADR1 which is N-terminal to the primary
phosphorylation site lying betw een residues 227-231.
ADR1 contains four regions in addition to the one betw een residues 227231 which are homologous to th e cAPK phosphorylation co n sen su s sequence*
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and could serve a s the second phosphorylation site. Since the 164 KDa fusion
proteins appeared to lack the secondary phosphorylation site, it w as
hypothesized that the secondary phosphorylation site occurs at a position Nterminal to the primary phosphorylation site at serine-230. Consistent with this
hypothesis, the putative secondary phosphorylation sites at threonine-226,
serine-211, serine-180, and serine-170 identified by homology to the cAPK
phosphorylation con sen su s sequence are N-terminally located with respect to
the primary phosphorylation site at serine-230. The putative phosphoacceptor
threonine-226 in the sequence Lys-Lys-Leu-Thr-Arg lies just N-terminal to the
primary phosphorylation site and occurs on the sam e chymotryptic peptide.
Since the 164 KDa ADR1-7C fusion protein digest contained no phosphorylated
peptides, threonine-226 can not be the the secondary site of in vitro
phosphorylation that w as observed.
The likelihood of the other sites serving a s potential phosphorylation sites
w as explored by examining results of previous studies on the kinetics of the in
vitro phosphorylation of synthetic peptides. Granot and colleagues73 found

th at the presence of a proline residue adjacent to the phosphoacceptor serine,
a s in the putative site located betw een residues 209-212 (Arg-Lys-Ala-Ser-Pro),
d ecreased the kcat/Km ratio of mammalian cAPK by - 5 X 1 0 6 relative to an
ADR1-like peptide. In other words, under identical labelling conditions the
*Arg-Arg-X-Ser-Y, where Y ten d s to be hydrophobic and X is any am ino acid.
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proline-containing peptide occurred at a rate ~10'6 that of the ADR1-like
peptide. It thus ap p ears unlikely that this site would be phosphorylated to any
m easurable extent in vitro in ADR1 . Of the two remaining sites, the site within
residues 177-181 (Arg-Lys-Asn-Ser-Ata) is most homologous to the cAPK
co n sen su s phosphorylation sequence and is therefore m ore likely to serve a s a
substrate for cAPK than is the site betw een residues 167-171 (Lys-Lys-Val-SerArg). Kemp and colleagues35 have shown that the two N-terminal arginine
residues within the phosphorylation consensus sequence are crucial to
substrate recognition by cAPK. Substitution of the N-terminal arginine with
lysine in a synthetic peptide resulted in an approximately 90-fold increase in the
Km of phosphorylation. In contrast, replacem ent of the C-terminal arginine with
lysine resulted in a 16-fold increase in the Km . On this basis the
phosphorylation site betw een residues 177-181 (Arg-Lys-Asn-Ser-Ala) might
be expected to serve a s a better substrate for cAPK than th e site between
residues 167-171 (Lys-Lys-Val-Ser-Arg). The results of previous kinetic
analyses using synthetic peptides a s substrates for in vitro phosphorylation by
cAPK therefore suggest that the observed secondary ADR1 phosphorylation
site w as serine-180. It should be em phasized that this prediction is b ased
solely on the in vitro kinetic properties of the bovine cAPK and does not
consider the possible effects which ADR1 tertiary structure may have on the in

vitro phosphorylation of serine-180. Further experim ents employing two-

dimensional peptide mapping techniques and/or sequencing of the relevant
phosphopeptide would be required to unambiguously identify the secondary
site of phosphorylation in ADR1.
The identification of a second site in ADR1 which is phosphorylated in vitro
brings up the interesting possibility that ADR1 is phosphorylated at more than
one site in vivo. The yeast ribosomal protein S10 has been shown to be
multiply phosphorylated74, a s has the large T antigen of simian virus 4075. In
the c a s e of large T antigen only one of the phosphorylation sites has b een
dem onstrated to functionally affect the protein76, while in the S10 protein
phosphorylation by cAPK appears to play no regulatory function74.
Replacem ent of serine-180 with an alanine residue using site directed
m utagenesis would help to clarify whether this putative secondary
phosphorylation site is involved in the regulation of ADR1.
The y east and mammalian (bovine) cAPK were observed to have slightly
different substrate specificities when used in the in vitro phosphorylation of the
fusion proteins. The yeast kinase phosphorylated the seq u en ce Arg-Arg-AlaSer-Ser-Ser (ADR1-2C) to a greater extent than the seq u en ce Arg-Lys-Ala-SerP he-S er (ADR1-5C) during the incubation period of the assay , in contrast, the
bovine kinase had the opposite preference, phosphorylating the seq u en ce Arg-
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Lys-Ala-Ser-Phe-Ser (ADR1 -5C) to a greater extent than the sequence ArgArg-Ala-Ser-Ser-Ser (ADR1-2*5). T hese results could arise from two quite
different phenom ena. First, although the affinity of the enzym es for each of the
two different seq u en ces could be nearly the sam e, the stiochiometries of
incorporation may be different. In other words, the two enzym es may share
similar Michealis constants (Km's) for the sequence Arg-Arg-Ala-Ser-Ser-Ser,
but the num ber of serines phosphorylated by the two enzym es may differ.
Alternatively, the difference observed in the levels of phosphate incorporation
may simply reflect that the kinases differ in their Km's for the two
phosphorylation sequences. Differences in the substrate specificities of the
y east and mammalian kinases might result from minor differences in their
respective active sites, white alterations in the stoichiometry of phosphorylation
would require that more gross functional differences exist betw een the two
enzym es. The yeast C1 catalytic subunit and mammalian catalytic subunits are
only approximately 50% homologous in the conserved C-terminal 310 amino
acids49, indicating that either explanation may be responsible for the observed
differences in substrate specificities. Further studies examining the
stoichiometry and kinetics of phosphorylation of the sequence Arg-Arg-Ala-SerS er-Ser by th e se two enzym es are required to clarify this issue.
The demonstration that ADR1 c/l3-galactosidase fusion proteins were less
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am enable to cAMP-dependent phosphorylation than were ADR1/I3galactosidase fusion proteins strongly supports the hypothesis that
phosphorylation is physiologically significant in the regulation of ADR1 activity.
Both the yeast and bovine cAPK catalytic subunits phosphorylated fusion
proteins containing the ADR1C amino acid substitutions poorly relative to fusion
proteins containing the ADR1 sequences. In vivo the ADR1C proteins may
therefore partially bypass glucose-dependent phosphorylation, in turn allowing
them to activate ADH2 transcription during glucose repression.
Krebs and colleagues77 have suggested that in order for a physiological role
for cAM P-dependent phosphorylation to be considered valid the following five
criteria m ust be met:
1. The protein must be phosphorylated by cAPK in vitro.
2. In vitro phosphorylation must lead to a modified function.
3. A stoichiometric correlation must exist betw een in vitro
phosphorylation and modified function.
4. Phosphorylation of the sam e protein m ust be dem onstrated in vivo in
response to a cAMP signal.
5. Modified function must be dem onstrated in response to a cAMP signal
in vivo.

The first of th ese criteria has been satisfied by th e demonstration that ADR1
is phosphorylated at two distinguishable sites in vitro by cAPK. The second
and third criteria proposed by Krebs et al., a s they pertain to ADR1, concern
correlating the stoichiometry of in vitro phosphorylation with a d ecreased ability
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to activate transcription of ADH2. Constitutive ADR1C mutants, which have an
increased ability to activate ADH2 transcription during glucose repression, were
less am enable to in vitro phosphorylation by cAPK than w as the wild-type
ADR1 protein, which is unable to activate transcription during glucose
repression (Figures 11 and 15). It thus appears that the degree of in vitro
phosphorylation of mutant ADR1C proteins can be correlated with a known
modified function in vivo. It is significant that strains carrying the ADR1-5C
mutation have slightly higher ADH II activities than strains carrying the ADR1-7C
mutation, although the ADR1-50 protein w as observed to be phosphorylated at
serine-230 while the ADR1-7C protein w as not. T hese d a ta do not necessarily
preclude the possibility that a stoichiometric relationship betw een ADR1
phosphorylation and ADR1 activity exists. The ADR1-5C and ADR1-70 proteins
may have tertiary or quaternary structures which are significantly different than
the wild-type ADR1 protein. T hese structural differences may affect their ADR1
activities independently of any effect which they have on the phosphorylation
state. The substitution of a leucine for the phosphoacceptor serine in the ADR17 ° protein may, for instance, have two opposing effects on ADR1 activity- it may
activate the protein by eliminating phosphorylation at residue 230, but it may
also diminish its ability to activate transcription by altering the tertiary structure
of the protein. Similarly, the substitution of a lysine for an arginine within the
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phosphorylation consensus sequence in ADR1-5C may not only d e crea se its
ability to act a s a cAPK substrate, but also enhance its function as a
transcriptional activator by causing a beneficial alteration in the protein
structure. Both of these scenarios imply that the phosphorylation seq u en ce
around serine-230 plays a role in ADR1 function even w hen not
phosphorylated, a s is indicated by the results of Bemis an d Denis23 discussed
below. Without knowing the effect the ADR1C mutations have on the structure of
the ADR1 protein it is impossible to attribute their phenotypes solely to the effect
which they have on the phosphorylation state of the protein. Determining
w hether there is a stoichiometric correlation between ADR1 phosphorylation
an d ADR1 activity will require determination of the phosphorylation state of
wild-type ADR1 during repressed and derepressed growth conditions. Criteria
2 and 3 may be more directly tested if an in vitro assay for ADR1 -m ediated
transcriptional activation becom es available.
Criteria 4 an d 5, a s they pertain to ADR1, address th e question of w hether a
cAMP signal modifies the in vi'vo activity of the ADR1 protein. Recent genetic
experim ents indicate that ADR1 activity is responsive to cAM P-dependent
phosphorylation in vivo (C. Denis, personal communication). As mentioned in
th e Introduction, yeast cAPK is com posed of a catalytic subunit and a cAMPresponsive regulatory subunit49,50. Three g e n es encode catalytic subunits,
TPK1. TPK2. an d TPK3. while a regulatory subunit is encoded by a single gene
91

designated BCY1. The ADH II activities of strains containing only one of the
catalytic subunits w ere compared to strains in which the g en e coding for the
regulatory subunit had been disrupted fb c v h . Strains with bcvl disruptions,
lacking a functional regulatory subunit, were expected to have unregulated
kinase activity, while those with the BCY1 allele were expected to have had
cAM P-dependent kinase activity. ADH2 derepression w as shown to decrease
ten to fifteen fold in two out of three strains with unregulated kinase activity
(Table 5). While the three catalytic subunits have been shown to be able to
functionally substitute for one another, there is som e indication that they differ in
their substrate specificities. For exam ple, unregulated TPK3 kinase activity has
no effect on other non-fermentative processes50 or on ADH2 derepression,
suggesting that the catalytic subunit encoded by TPK3 may be less active or not
recognize ADR1 and other substrates during non-fermentative growth.
Denis next used strains containing the ADR1-5C and ADR1-7C in an effort to
show that the effect of unregulated kinase on ADH2 expression w as mediated
through th e ADR1 protein. He reasoned that ADR 1-5° would be more sensitive
to unregulated kinase activity than ADR 1-7° b ased on the fact that th e latter
mutation encodes a protein lacking the phosphoacceptor serine. Under
d erep ressed growth conditions unregulated TPK1 kinase activity d ecreased
ADH II activity in the ADR1-5C strain 4.4-fold, while it decreased ADR1-7C
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dependent activity 2.4-fold (Table 5). Although less dramatic, the glucose
repressed ADH II activities show a similar trend with the ADR1-5C strain
decreasing 2.2-fold com pared to 1.5-fold for the ADR1-7C strain. Unregulated
TPK3 kinase activity did not affect ADH II expression under derepressing
conditions, consistent with the aforementioned suggestion that this kinase is
less active or recognizes ADR1 poorly during non-fermentative growth. Under
glucose-repressed growth conditions ADR 1-5° -dependent ADH II activity was
d ecreased 4.7-fold by unregulated TPK3 kinase activity, while the ADR1-7C dependent activity decreased only 1.4-fold.
Taken together the in vitro phosphorylation studies presented in this work
and the genetic analysis performed by Denis clearly dem onstrate that ADR1
function is modified by cAMP-dependent phosphorylation in vivo.
Results previous to this work indicated that the glucose repression of ADH2
occurs at the level of transcription16. The isolation24 and characterization27,32 of
dominant constitutive ADR1C mutations which allow ADH2 expression to
partially esca p e glucose repression implies that the ADR1 protein is responsive
to a glucose repression signal.
There are two basic m echanisms by which a glucose repression signal could
affect a regulatory protein required for transcription of ADH2. The first would be
to alter the cellular concentration of the ADR1 protein by affecting its
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Table 5.
Effect o f BCY1 G en e Disruption on APH2 E xp ression
Strains used in the preparation of this table are described in detail in the
reference from which it w as taken (Cherry et al.27). ADH II activities were
determ ined a s described16 following growth of cultures overnight at 30° C.
Culture mediums contained YEP medium (2% yeast extract, 1% Bacto-peptone,
20 mg/L adenine and uracil) supplemented with either 8% glucose or 3%
ethanol. Each value represents the average of five to eleven determinations.
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Table 5

relev an t
g e n o ty p e

Glucose

ADH II activitv (mU/mg)
fold
Ethanol
reduction

41

JPK1

6000
\ 14

)o.91
TPK1 bcvl

45

440

TPK2

36

3800
1 1.3

)1 5

T P K 2 te l

28

260

TPK3

4.2

3300
)o.79

TPK3 bcvl

TPK1

ADR1-5.C

}o.97

5.3

3400

610

8700
}2.2

}4.4

TPK1 bcyl

ADR1-50

280

2000

TPK1

ADR 1:7?

105

15,300
}2.4

} l.5
TPK1 bfijtl

ADR1-7C

69

6500

TPK3

ADR1-5C

340

7400
}0.96

} 4 ,7

TPK3 bcvl

ADR1-5C

72

7900

TPK3

ADftLZc

90

8400
}1.4

T P K 3 im

ADR1-7C

fold
reduction

}0.94
8900

66
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transcription, translation, or rate of degradation. The E. coli lamda phage
provides an interesting exam ple of a transcriptional control mechanism by
which the cellular concentration of the lam bda repressor is autoregulated78,93.
Transcription of the lytic g e n e s and the gen e encoding the lambda repressor
(cl) are repressed by the lam bda repressor protein when its concentration is
high. W hen the cellular concentration of lambda repressor becom es low,
repressor binding is reduced and transcription of the ci g en e is stimulated.
Cellular signals can also modulate the cellular concentration of regulatory
proteins translationally, a s h a s been dem onstrated for the GCN4 protein in
an

yeast . GCN4 is a positive regulatory protein required for transcription of
amino acid biosynthetic g e n e s in yeast79. The cellular signal, amino acid
starvation, rem oves a block on the translation of the GCN4 protein and c a u se s
an increased rate of translation80. The resulting increase in GCN4 protein
concentration allows transcriptional activation of approximately 50 biosynthetic
genes. Although there are currently no exam ples of a cellular signal which
cau ses an increased rate of regulatory protein degradation, several enzym es in
yeast are known to be preferentially degraded proteolytically in response to the
addition of glucose to the growth medium. In the c a se of the gluconeogenic
enzyme fructose-1,6-bisphosphatase glucose induced inactivation is at least
partially m ediated by a cAM P-dependent phosphorylation step81,82. T here
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appears to b e a direct correlation between the degree of subunit
phosphorylation, which inactivates the enzyme, and the rate of its subsequent
proteolytic degradation01,02,41. This m echanism, term ed catabolite inactivation,
may also be used by the cell to selectively degrade regulatory proteins which
are not required during growth on fermentable carbon sources, such a s ADR1.
The second way in which a glucose repression signal could affect ADR1
activity is by inducing a transition of the protein from an active state to an
inactive state. By regulating the activity of the protein rather than its synthesis or
degradation, such a m echanism would offer the advantages of being faster and
more energetically economical, since no de novo protein synthesis would be
required. In E. coli transcription of several glucose repressed operons requires
that the catabolite activator protein (CAP) be bound to operator seq u en ces03*06.
CAP must bind cAMP before it can bind to DNA and activate transcription. In E.
coli intracellular cAMP levels are increased in the ab sen ce of glucose. W hen

cells are grown in the a b sen ce of glucose, cAMP levels are elevated and CAP
is activated. Thus the glucose repression of operons such a s lac and a ra is
mediated through low cAMP levels which prevent CAP from activating
transcription. The E. coli lac repressor provides another exam ple in which a
cellular signal modifies th e activity of a regulatory protein. This negative
regulatory protein binds to the lac operator and sterically blocks transcription of
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the lac operon83. W hen ceils are exposed to lactose an inducer is produced,
allolactose, which is bound by the lac repressor causing its release from the
operator.
In the exam ples discussed thus far the cellular m essengers interact directly
with regulatory proteins which bind to DNA and affect transcription. A cellular
signal may also interact with a regulatory protein not directly involved with DNAbinding, but which eventually results in an effect on transcription. The galactose
metabolism system in yeast, for example, is largely controlled by the positive
regulatory protein GAL4 and the negative effector GAL8087. Transcription is
dependent on binding of the GAL4 protein to upstream activating seq u en ces
(UAS's) located upstream from the site of transcription initiation88,89. In the
ab sen ce of galactose the GAL80 protein binds to the GAL4 protein and blocks
its activator function90. Since GAL80 does not bind to the UAS's and binding of
GAL80 to GAL4 d o es not disrupt GAL4 binding to DNA89, it is presum ed that
GAL80 m asks som e functional region of GAL4 which normally interacts with the
transcriptional complex. In the presence of galactose, GAL80 is altered such
QA

that it no longer binds to GAL4 and transcription is activated . It is unclear
whether GAL80 interacts directly with galactose, but it is evident that som e
cellular signal indicating the availability of galactose is transm itted via protein*
protein interactions to activate transcription of the g e n es required for galactose
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metabolism.
Several studies suggest that ADR1 is not transcriptionally or translationally
controlled in response to a glucose repression signal. ADR1 mRNA h as been
dem onstrated to be constitutively synthesized independent of the carbon source
in the growth medium32. ADR1C mutations allow ADH2 transcription to partially
esca p e glucose repression. The characterization of th e se mutations a s single
amino acid substitutions32,27 suggests that ADR1 is translated under
fermentative conditions. Therefore if the cellular concentration of ADR1 is
controlled, it must occur through a post-translational mechanism.
Although it appears quite clear that the glucose repression of ADH2 is in part
mediated by phosphorylation of the ADR1 protein, the m echanism by which
phosphorylation reduces the ability of ADR1 to activate ADH2 transcription
rem ains unclear. A recent report by Bemis and Denis23 in which they studied
the effects of various ADR1 gen e truncations on ADH2 expression clarifies the
role which the phosphorylation region plays in ADR1 function. Strains
expressing only the N-terminal 220 amino acids of ADR1 (ADR1-220) did not
allow ADH2 to escap e glucose repression, although the truncated protein w as
capable of activating ADH2 under derepressing conditions. Increased
expression of ADR1-220 did not allow ADH2 expression to escap e glucose
repression. In contrast, increased expression of any ADR1 proteins containing
the phosphorylation site at serine-230 did allow ADH2 expression to bypass
99

glucose repression. From these data it appears that the phosphorylation site at
serine-230 is required for ADR1 to bypass ADH2 glucose repression, but is not
required for activation of ADH2 transcription during derepressed growth.
How can bypassing glucose repression of ADH2 require the ADR1
phosphorylation region, yet not allow ADH2 expression to escap e glucose
repression when rem oved? Bemis and Denis23 suggest that this apparent
paradox results from the decreased ability of the ADR1-220 protein to activate
transcription a s com pared to proteins which contain the phosphorylation region.
They found that the ADR1-220 protein w as 2-3 fold less active than proteins
containing the N-terminal 253 or 272 amino acids of ADR1 (ADR1-253 and
ADR1-272) under derepressing conditions. T hese results indicate that the
phosphorylation region, while negatively affected by phosphorylation during
glucose repression, plays a positive role in ADR1 function. The ADR1 -220
protein m ay be able to activate transcription under derepressed conditions
b ecau se other proteins necessary for ADH2 transcription are present and
active. Under glucose growth conditions increased expression of ADR1-220
d o es not allow glucose repression to b e bypassed because, unlike larger ADR1
proteins, this less active truncated ADR1 protein requires other factors which
are present only during derepression. Thus it ap p ears that phosphorylation
d o es not wholly inactivate ADR1, but merely diminishes the positive role which
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the phosphorylation region plays in ADR1 function.

Of the m any positive roles it could play, the phosphorylation region may
facilitate the binding of the ADR1 protein to DNA. The DNA-binding zinc finger
motif found betw een residues 99-155 appears to be necessary but not sufficient
for binding of ADR1 to the ADH2 upstream seq u en ces (E.T. Young, personal
communication) indicating that other regions of the protein are necessary.
Simian virus 40 large T antigen, a protein involved in viral g en e regulation and
replication, h a s been suggested to be regulated through a phosphorylation
m echanism 76. When dephosphorylated, large T antigen binds to the viral origin
of replication in vitro with several-fold higher affinity than d o es the
phosphorylated protein. Phosphorylation may play a similar role in the DNAbinding properties of ADR1. Since 24% of the amino acids betw een the Cterminal zinc finger and the primary phosphorylation site at amino acid 230 are
basic residues, while only 4% are acidic (18 of 75 versus 4 of 75), it is tempting
to speculate that the overall basic nature of this region aids DNA binding
through electrostatic attraction. Addition of an acidic phosphate group, by
decreasing the positive character of the region, may diminish such an attraction.
Deletion of the basic region, a s in the ADR1-220 protein discussed above,
would also b e expected to diminish ADR1 activity. The first step in testing this
hypothesis would be to determ ine whether the in vitro phosphorylation of
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ADR1 affects its ability to bind to the ADH2 UAS.
The phosphorylation region may also be involved in the transcriptional
activation properties of ADR1. If ADR1 contacts a protein in the transcription
complex directly through the phosphorylation region, phosphorylation may
disrupt such a contact. Alternately, the phosphorylation region could contact
another protein which is required for stimulation of transcription, but which is not
directly involved in the transcriptional machinery. Yeast regulatory proteins
GAL4 and GCN4 have been suggested to activate transcription by contacting
the transcriptional machinery through acidic dom ains91,92. The basic
phosphorylation region of ADR1, in order to play a role in transcription
activation, may require contact with a "helper" protein which contains the
necessary acidic domain. To be consistent with the results of the ADR1
truncation studies performed by Bemis and Denis discussed above, the helper
protein must also either interact with ADR1 through regions other than the
phosphorylation region around serine-230 or not be absolutely required for
ADR1 function during derepression.
Finally, the phosphorylation region could be important to ADR1
oligomerization. ADH II activities in ADR1C. adr1-x heterologous diploid strains
su g g est that ADR1 monomers interact with one another to activate transcription
of ADH2 (C. Denis, personal communication). In addition, th e palindromic
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nature of the ADH2 DNA binding site sug g ests that a symmetrical oligomer is
required for binding. Multimers of ADR1 may have better DNA binding or
transcriptional activation properties than do monomer ADR1 molecules. A good
exam ple of the possible effects of phosphorylation on oligomerization is
provided by glycogen phosphorylase, the enzyme which catalyses th e first step
in glycogen metabolism. The transition between an active dimer and a lessactive monomer has been suggested to be controlled by the opposing actions
of phosphorylase kinase and phosphorylase phosphatase44.
Several lines of evidence indicate that while phosphorylation of ADR1 at
serine-230 is responsible for som e of the observed d e crea se in ADR1 activity
during glucose repression, there must exist other factors which contribute to the
glucose repression of ADH2. The ADH II activity in ADR1-7Q-containino strains
w as still decreased by unregulated kinase activity, despite the a b se n c e of the
phosphoacceptor serine at amino acid 230. This d ata implies that cAMPdependent phosphorylation occurs at another site in ADR1 or that
phosphorylation of som e other factor is important to glucose repression.
Furthermore. ADH2 expression in strains carrying any of the ADR1C mutations
never completely b ypasses glucose repression (Table 1). Similarly, increased
d o sa g e of the ADR1 gene allows ADH2 expression to significantly e sca p e
glucose repression, yet glucose repression of ADH2 is still evident even when
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ADR1 is present at 80 c o p ie s . Factors other than ADR1 must therefore be
involved in the glucose repression of ADH2.
At least two other g e n es with pleiotropic action are known to be required for
ADH2 expression, CCR1 and CCR418'21. Defects in either of th ese g en es
d ecrease the activities of a num ber of gluconeogenic enzym es which are
glucose repressed. The CCR1 and CCR4 proteins may therefore be involved in
the general transm ission of a glucose repression signal. Genetic analysis has
shown that CCR1 acts through or with ADR1 to activate ADH2 transcription21.
CCR1 en co d es a protein kinase21, but appears not to act through the primary
phosphorylation site at amino acid 230 since truncated ADR1 proteins lacking
oo

this site remain sensitive to defects in the CCR1 gen e . CCR1 may affect
phosphorylation of ADR1 at som e other site either directly or indirectly or may
act on som e other protein required for the derepression of glucose-repressed
genes. The other positive regulatory element, CCR4, is thought to act
independently of ADR1 at seq u en ces downstream of the TATA promoter
elem ent in ADH294. B ecause CCR4 is a pleiotropic effector it may comprise
part of a general transcription complex which is sensitive to a glucose
repression signal. There exists genetic evidence that CCR4 is inactivated
during glucose repression by the action of two negative effectors, CRE1 and
CRE221. The cellular signals which CRE1 and CRE2 respond to and the
m echanism of their action on CCR4 is unknown.
104

Much work rem ains if the role of phosphorylation in ADR1 regulation is to be
fully understood. Among the m ost pressing experiments are determining the in
vivo phosphorylation state of the ADR1 protein during repressed and

d erep ressed growth conditions, the effect of ADR1 phosphorylation state on
ADRVs DNA binding properties, and using site directed m utagenesis to
determ ine th e possible significance of the putative secondary phosphorylation
site. More long-term goals should be directed toward gaining a better
understanding of how phosphorylation molecularly affects the interaction of
ADR1 with DNA or other proteins of the transcription complex.
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Appendix A
Sm all s c a le plasm id prep
(adapted from H. C. Birnboim and J. Doly (1979) Nucleic Acids Res. 7,1513.)
1. Grow 1.5 ml cultures overnight in L broth (10 g tiyptone, 5 g yeast extract, 5 g
NaCI
per liter) supplem ented with appropriate antibiotic (ampicillian to 50 pg/ml).
2. Pellet cells by centrifugation for 1 minute in microcentrifuge tubes.
3. Decant L broth and air dry pellet by inversion on absorbant towels. Dried
pellets should be loosened by vortexing two tubes together prior to next
step.
4. Add 100 pi cold lysozyme solution (25 mM Tris-CI, pH 8 ,1 0 mM EDTA, 50
mM glucose, 2 mg/ml fresh lysozyme), mix thoroughly, and incubate on ice
10-30 minutes.
5. Add 200 pi NaOH-SDS (0.2 N NaOH, 1% SDS, freshly prepared by mixing
1 ml 1N NaOH, 0.5 ml 10% SDS, 3.5 ml water) and mix by vortexing.
Incubate on ice 5 minutes.
6 . Add 150 pi 3M sodium acetate, pH 4.8 and vortex in inverted position for 10
seconds at low sp e ed . Vigorous mixing will result in contamination with
genomic DNA. Incubate on ice 20-60 minutes.
7. Centrifuge at 4° C. for 10 minutes and remove supernatant to a fresh
microtube (avoiding the pellet) using a 1 ml micropipet. This supernatant
contains the plasmid DNA.
8 . Add 1 ml cold ethanol to recovered supernatant, mix gently, and incubate at
4 ° C. for 15 minutes. This is a good stopping point, if necessary.
9. Centrifuge for 15 minutes at 4 ° C., decant ethanol supernatant, and allow
pellets to air-dry by inversion on paper towels.
10. R esuspend dried pellets in 400 pi TE (10 mM Tris-HCI, pH 8.0,1 mM EDTA)
11 .Extract resuspended pellet with an equal volume of TE-saturated
phenol (phenol:chloroform:isoamyI alcohol; 50:1:1), centrifuge 2 minutes,
and carefully remove top phase to a fresh microtube. R epeat extraction with
TE-saturated chloroform until chloroform phase (bottom) is clear. O ne
extraction is usually sufficient.
12. Add 0.1 volume 3 M sodium acetate (about 40 pi) and fill tubes with cold
ethanol. Incubate at room tem perature 30 minutes to overnight.
13. Centrifuge for 30 minutes to recover precipitated plasmid and dry pellet first
by inversion on paper towels, then to com plete dryness in Savant S peedVac. W ash dried pellets with 0.5 ml cold 70% ethanol, centrifuge and dry a s
above.
14. R esuspend dried pellet in 40-50 pi TE buffer. 5 pi of this final plasmid
solution should be sufficient for restriction digestion and visualization on an
a g aro se gel.
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Appendix B
R estriction Enzym e Buffers:
LS Buffer flow salt)
0.66 ml 1M MgCl2
0.66 ml 1M Tris buffer, pH 7.5
8.68 ml sterile w ater
MS Buffenfmedium salt, [ N a d l ^ ^ 100 mM)
0.66 ml 1M MgCl2
0.66 ml 1M Tris buffer, pH 7.5
1.26 ml 5M NaCI
7.42 ml sterile w ater
HS Buffer fhioh salt, [NaCilfjna|= 150 mM)
0.66 ml 1M MgCl2
0.66 ml 1M Tris buffer, pH 7.5
1.89 ml 5 M NaCI
6.79 ml sterile w ater
KS Buffer (potassium salt, [KCI^jna|= 100 mM)
0.66 ml 1M MgCl2
0.66 ml 1M Tris buffer, pH 7.5
6.28 ml 1MKCI
2.40 ml sterile w ater
To m ake active buffer (2X): 20 pi sterile bovine serum albumin (1 mg/ml,
[BSA]fjna(= 0.45 pg/ml), 10 pi 1/100 dilution 6-m ercaptoethanol (14.26 M
[BME)jjna|» 32 mM), 14 pi selected restriction buffer ([MgCl2]fina|» 21 mM,
[ T t e l f j n a r 21 m M )-

114

Appendix C
DNA Fragm ent Preparation and Ligation R eaction s
1. Separate restriction fragm ents on a 0.6% low-melting point agarose (LMP
agarose, BRL or S eaPlaque agarose, FMC) run at 4 ° C. with TAE buffer
(SOX 121 g Tris base, 11.7 g EDTA (acid form) and ~26.5 ml glacial acetic
acid. Final pH should be 8.2.). U se narrow gel slots; concentrate sam ples by
ethanol precipitation if necessary.
2. Stain gel with ethidium bromide (for a 10 X 10 cm gel u se about 1 pg in 100
ml cold TAE running buffer). While gel is staining label and tare sufficient
microtubes to accom odate each fragment to be excised.
3. B ands should be easily visible using a low-power UV light box. Carefully
excise fragm ents of interest from the gel using a clean razor blade and
transfer to labeled microtubes. Work quickly to minimize exposure of the
DNA to damaging UV light. Photograph gels after band excision for a
record.
4. Determine the weight of the agarose band and add 5 X the weight of TE (i.e.
a gel slice weighing 0.1 g will get 500 pi TE). Add 1 pg y east tRNA a s a
carrier (omit if the fragment is to be used a s a probe).
5. Heat gel slice at 65° C. for 10 minutes to melt agarose and release the
fragment.
6 . Cool and extract with an equal volume STE-saturated phenol (no
chloroform! STE» TE with 0.15 M NaCI). R epeat extraction with
phenol:chloroform:isoamyI alcohol, then chloroform.
7. Add 0.1 volume 3 M sodium acetate and 2 volumes ethanol. Incubate
overnight at 4 ° C. for good recovery. Centrifuge for 30 minutes at 4° C to
recover fragment.
8 . R esuspend fragment in 10 pi TE.
9. Run 2 pi of DNA fragm ents to be ligated side-by-side on a microscope slide
ag aro se gel. Photograph and visually determine relative concentrations.
10. Mix 1 pi 10X ligation buffer (300 mM Tris, pH 7 .6 ,1 0 0 mM MgCl2 . 50 mM
dithiothreitol), 1 pi 10 mM ATP, 1 pi T4 DNA ligase (approximately 100 units,
New England Biolabs) and DNA fragm ents to b e ligated in a 10 pi reaction
volume. Insert to vector ratios should be betw een 2:1 and 5:1 for efficient
ligation. Blunt end ligations should be performed at 4<>-12° C., while
cohesive end ligations work better at 16° C. Ligations should be allowed to
react overnight, and should be diluted such that the estim ated am ount of
ligated DNA used in transformation with BRL com petent cells is ~10 ng.
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Appendix D
E stim ated charge/frlctlonal coefficien t ratios for p o s s ib le p ep tid es
produ ced by chym otryptic d ig estio n of ADR1, ADR1-2C, ADR1-5C
and ADR1-7®
The theoretical mobility (U) of a macromolecule during zonal electrophoresis
is a function of the charge on the macromolecule (ze) and its frictional
coefficient (f)99:
U= z e / f
Due to num erous complications introduced by interaction of
m acromolecules with solvent ions, endosm osis of the solvent, and distortion of
the ion field around the macromolecule a s it moves through the electrophoretic
medium, there is no simple theoretical treatm ent which can accurately explain
the observed mobility of proteins during electrophoresis. The calculations
performed here are provided simply a s a reference for comparison to observed
mobilities of peptides on the 50% pH 3 gel system of W est and Bonner68.
To u se the formula presented above, the charge (p) and frictional
coefficients for all the ADR1 and ADR1C chymotryptic peptides capable of being
phosphorylated w ere estim ated. For estimations of p under the gel conditions
of pH 3, the following assum ptions were made: N-terminal amino groups were
assu m ed to be fully protonated and contributed +1 charge per peptide ; lysine
and arginine residues were assum ed to be fully protonated and contributed +1
charge per acidic residue: C-terminal carboxyl groups were assu m ed to
contribute -0.1 charge per residue; and finally, phosphate groups were
assu m ed to contribute -0.86 charge p er phosphate incorporated. Due to the
effect of electrostatic interactions may have on the ionization of charged groups
(effectively lowering or raising pKa 's), charges w ere calculated for each peptide
containing one and two phosphate groups. T hese two values may be used a s a
possible range of variability.
Frictional coefficients w ere estim ated using two different techniques. The
first simply assum ed that the frictional coefficients of the various peptides w ere
directly proportional to the length of the peptide. The second estim ate assum ed
that the frictional coefficients of the peptides is proportional to their molecular
weight raised to the 2/3 power. The latter estim ate is based on empirical
observations of the mobility of peptides during thin layer electrophoresis100.
R esults of th e se calculations are presented in Table A.
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Table A
Estim ated charge/frictlonal coefficien t ratios for p o s s ib le p ep tid es
produced b y chym otryptic d ig estio n of ADR1, ADR1-2C, ADR1-5C
and ADR1-7®
Column A:

S equence of predicted phosphorylated peptides produced by
chymotryptic digestion of ADR1/, ADR1-20/, ADR1-50/ and ADR17^/13-galactosidase fusion proteins.

Column B:Calculated molecular weights of the predicted peptides.
Column C:ADR1 residues which the peptides in column A span.
Column D:Number of lysine and arginine residues within the peptide.
Column E:Calculated charge on the peptide at pH 3 with no phosphate groups
incorporated, p.
Column F: Calculated charge on the peptide at pH 3 with one phosphate
groups incorporated, p1.
Column G:Calculated charge on the peptide at pH 3 with two phosphate groups
incorporated, p2.
Column H:Number of residues in the peptide, N.
Column I: Calculated charge on the peptide at pH 3 with one phosphate
groups incorporated divided by the length of the peptide, p1/N.
Column J: Calculated charge on the peptide at pH 3 with two phosphate groups
incorporated divided by the length of the peptide, p2/N.
Column K: Calculated charge on the peptide at pH 3 with one phosphate
groups incorporated divided by the molecular weight of the of
peptide to the two-thirds power, p1/MWA2/3.
Column L: Calculated charge on the peptide at pH 3 with two phosphate groups
incorporated divided by the molecular weight of the of peptide to the
two-thirds power, p2/MWA2/3.
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